REVIEW

Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections [version 1; peer review: 1 approved with reservations]

Philip M. Bath^{1,2}, Christopher M. Coleman³, Adam L. Gordon^{4,5}, Wei Shen Lim⁶, Andrew J. Webb⁷

¹Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, Notts, NG7 2UH, UK

²Stroke, Nottingham University Hospitals NHS Trust, Nottingham, Notts, NG7 2UH, UK

³Division of Infection, Immunity and Microbes, School of Life Sciences, University of Nottingham, Nottingham, Notts, NG7 2UH, UK

⁴Unit of Injury, Inflammation and Recovery Sciences, University of Nottingham, Derby, Derbyshire, DE22 3NE, UK

⁵NIHR Applied Research Collaboration-East Midlands (ARC-EM), Nottingham, Notts, UK

⁶Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, UK

⁷Clinical Pharmacology, School of Cardiovascular Medicine & Sciences, Kings College London British Heart Foundation Centre of Research Excellence, St Thomas' Hospital, London, SE1 7EH, UK

V1 First published: 05 Jul 2021, 10:536
<https://doi.org/10.12688/f1000research.51270.1>

Latest published: 22 Oct 2021, 10:536
<https://doi.org/10.12688/f1000research.51270.2>

Abstract

Although the antimicrobial potential of nitric oxide (NO) is widely published, it is little used clinically. NO is a key signalling molecule modulating vascular, neuronal, inflammatory and immune responses. Endogenous antimicrobial activity is largely mediated by high local NO concentrations produced by cellular inducible nitric oxide synthase, and by derivative reactive nitrogen oxide species including peroxynitrite and S-nitrosothiols. NO may be taken as dietary substrate (inorganic nitrate, L-arginine), and therapeutically as gaseous NO, and transdermal, sublingual, oral, intranasal and intravenous nitrite or nitrate. Numerous preclinical studies have demonstrated that NO has generic static and cidal activities against viruses (including β -coronaviruses such as SARS-CoV-2), bacteria, protozoa and fungi/yeasts *in vitro*. Therapeutic effects have been seen in animal models *in vivo*, and phase II trials have demonstrated that NO donors can reduce microbial infection. Nevertheless, excess NO, as occurs in septic shock, is associated with increased morbidity and mortality. In view of the dose-dependent positive and negative effects of NO, safety and efficacy trials of NO and its donors are needed for assessing their role in the prevention and treatment of infections. Trials should test dietary inorganic nitrate for pre- or post-exposure prophylaxis and gaseous NO or oral, topical or intravenous nitrite and nitrate for treatment of mild-to-severe infections, including due to SARS-CoV-2 (COVID-19). This review summarises the evidence base from *in vitro*, *in vivo* and early phase clinical studies of NO activity

Open Peer Review

Approval Status

	1	2	3
version 2 (revision) 22 Oct 2021	view	view	view
version 1 05 Jul 2021	view		

1. **Khosrow Kashfi** , City University of New York School of Medicine, New York, USA
2. **Jan Mohammad Mir** , Islamic University of Science and Technology, Awantipora, India
3. **Steffen B. Wiegand**, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
University Hospital, LMU, Munich, Germany

Any reports and responses or comments on the article can be found at the end of the article.

in viral, bacterial, protozoal and fungal infections.

Keywords

Bacteria, COVID-19, fungus, nitric oxide, nitrate, nitrite, protozoa, virus

This article is included in the **Pathogens** gateway.

Corresponding author: Philip M. Bath (Philip.Bath@nottingham.ac.uk)

Author roles: **Bath PM:** Conceptualization, Project Administration, Writing – Original Draft Preparation; **Coleman CM:** Writing – Review & Editing; **Gordon AL:** Writing – Review & Editing; **Lim WS:** Writing – Review & Editing; **Webb AJ:** Writing – Review & Editing

Competing interests: PMB is Stroke Association Professor of Stroke Medicine and is a NIHR Emeritus Senior Investigator; he is chief investigator of the BEET-Winter and PROTECT-CH trials and was chief investigator of 6 trials of GTN in acute stroke; he has received honoraria as Chair of the Steering Committee for DiaMedica. AG is co-chief investigator of the PROTECT-CH trial. AJW holds shares in HeartBeet Ltd, which receives a royalty from James White Drinks Ltd, which manufactures active nitrate-containing and placebo nitrate-depleted beetroot juice used in clinical studies. All the authors are investigators in the BEET-Winter trial. The authors have no association with any of the companies mentioned in this review.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Bath PM *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Bath PM, Coleman CM, Gordon AL *et al.* **Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections [version 1; peer review: 1 approved with reservations]** F1000Research 2021, **10**:536 <https://doi.org/10.12688/f1000research.51270.1>

First published: 05 Jul 2021, **10**:536 <https://doi.org/10.12688/f1000research.51270.1>

Introduction

Nitric oxide (NO), an inorganic molecule, is generated endogenously by prokaryotes and eukaryotes from L-arginine by a family of NO synthase enzymes (NOS; Table 1.1).¹ In higher animals, it is also generated by reduction of dietary and endogenous nitrate (NO_3^-) to nitrite (NO_2^-) and thence NO (Table 1.2). NO is a pleiotropic signalling molecule involved in vascular, neuronal and metabolic regulation and has multiple physiological effects including lowering blood pressure, increasing exercise performance, and reversing metabolic syndrome. Underlying these processes, NO modulates multiple cell types including leucocytes,² platelets,³ endothelial cells and smooth muscle cells, and neuronal, cardiac and renal function. Three isoforms of NOS exist in eukaryotes: neuronal (nNOS, NOS1), inducible (iNOS, NOS2) and endothelial (eNOS, NOS3). In multicellular organisms, NOS1-3 produces NO that broadly mediates neurotransmission, cyto-toxicity and vascular regulation respectively. Within cells, NO interacts with mitochondrial respiration, activates metabolic regulatory pathways and reduces oxidative stress.

As people age, endothelial-derived vascular NO levels fall and so vascular function declines causing relative endothelial dysfunction, pro-platelet and pro-inflammatory effects, and increased smooth muscle proliferation. Vascular NO levels are even lower in people with established vascular disease, *e.g.* those with stroke.^{4,5} Numerous viruses (including adeno, Cocksackie, coronavirus, cytomegalovirus, echovirus, herpes simplex, human T-cell leukaemia virus type-1, human immunodeficiency virus, influenza, measles, mumps, polio) and bacteria (*Leptospira* spp.) can infect⁶⁻⁸ and damage endothelium and so further reduce vascular NO levels. This also appears to occur in SARS-CoV-2 infection.⁹

Most physiological effects of NO are modulated by cyclic guanosine monophosphate (cGMP, second messenger),^{10,11} and terminated when cGMP is metabolised by phosphodiesterase-5 (PDE5). This combined L-arginine/nitrate-NO-cGMP-PDE5 system (or nitric oxide system) comprises one of two key vasculo-protective pathways, the other being the prostaglandin-cyclic adenosine monophosphate-phosphodiesterase-3 pathway (PG-cAMP-PDE3, or prostacyclin system, see below).

The NO system may be enhanced or stimulated exogenously with substrate (L-arginine, organic nitrate, inorganic nitrite or nitrate), NO gas, and PDE5 inhibitors. These can be inhaled or administered *via* transdermal, sublingual, oral, intranasal or intravenous routes (see below). Since endogenous NO generated by inducible NOS plays a key role in defence against multiple microbial pathogens (including viruses, bacteria, protozoa and fungi/yeast), this raises the possibility that exogenous NO might have therapeutic potential as a broad-spectrum antimicrobial, and this is the topic of this review.

Methods for the review

There are numerous publications in this research area and our intention was not to perform a systematic review of these; rather we present exemplars from the research field. We identified publications relating to the effect of NO on viruses, bacteria, protozoa and fungi/yeasts from searches of our own reference libraries, PubMed and Google, and reference lists given in earlier reviews and commentaries.¹²⁻²⁰

The primary searches for relevant studies for inclusion were done through PubMed from inception to 4 May 2021, in English with the following disease terms: “microbe” or “virus” or “bacteria” or “protozoa” or “fungi” or “yeast”. The results of these searches were crossed with the drug terms “nitric oxide” or “nitrite” or “nitrate”, and the identified abstracts were screened by one or more researchers. Earlier studies, including published reviews, were also identified from the files of the senior author. Studies included *in vitro*, *in vivo* and clinical trials. Although other drug classes, such as statins and angiotensin-converting enzyme inhibitors, enhance endothelial production of nitric oxide, their main effects are mediated through other pathways, and we have not assessed them here even though they may attenuate microbial disease severity.

Chemistry and biology of nitric oxide

NO is a small diatomic hydrophobic colourless gas that diffuses easily and has a short half-life. With an unpaired electron ($\text{NO}^\bullet$), it is a free radical and so is chemically reactive and unstable in the presence of oxygen and superoxide producing reactive nitrogen oxide species (RNOS). In reality, the chemistry of NO is more complex and it exists in several redox forms: nitrosonium cation (NO^+), NO ($\text{NO}^\bullet$) and nitroxyl anion NO^- .²¹

As an inorganic molecule, its central role in biology as a signalling molecule was only discovered in the 1980s,²² the identification of which led to the Nobel Prize for Physiology and Medicine in 1998.²³ Ironically, the medicinal use of NO in the form of glyceryl trinitrate (GTN) for angina prophylaxis antedates the modern understanding of the biological synthesis and role of NO by more than a century.²⁴

Table 1. Chemical equations relevant to the nitric oxide system.

No.	Substrate	Product	Enzyme	Biochemical equation
1.	L-arginine	NO	Nitric oxide synthase	$2 \text{ L-arginine} + 3 \text{ NADPH} + 3 \text{ H}^+ + 4 \text{ O}_2 \rightarrow 2 \text{ L-citrulline} + 2 \text{ NO} + 3 \text{ NADP}^+ + 4 \text{ H}_2\text{O}$
2.	Dietary nitrate	NO		$\text{NO}_3^- + \text{e} + 2 \text{ H}^+ \rightarrow \text{H}_2\text{O} + \text{NO}_2^-$ $2 \text{ NO}_2^- + 2 \text{ H}^+ \rightarrow 2 \text{ HNO}_2 \rightarrow \text{N}_2\text{O}_3 + \text{H}_2\text{O}$ $\text{N}_2\text{O}_3 \rightarrow \text{NO} + \text{NO}_2$
3.	NO	Peroxynitrite		$\text{NO}^\bullet + \text{O}_2^{\bullet-} \rightarrow \text{OONO}^-$
4.	Superoxide	Hydrogen peroxide	Superoxide dismutase	$\text{O}_2^{\bullet-} \rightarrow \text{O}_2 + \text{H}_2\text{O}_2$
5.	Nitrite	Peroxynitrous acid		$\text{NO}_2^- + \text{H}_2\text{O}_2 \rightarrow \text{ONOOH}$
6.	NO	Nitrogen dioxide		$2 \text{ NO} + \text{O}_2 \rightarrow 2 \text{ NO}_2$; $\text{ONOOH} \rightarrow \text{NO}_2 + \text{OH}$
7.	NO	Dinitrogen trioxide		$\text{NO} + \text{NO}_2 \rightarrow \text{N}_2\text{O}_3$
8.	Nitrogen dioxide	Dinitrogen tetroxide (amyl)		$2 \text{ NO}_2 \rightarrow \text{N}_2\text{O}_4$
9.	Hydrogen peroxide	Hydroxyl radicals		$\text{H}_2\text{O}_2 \rightarrow \text{OH}^- + \text{OH}^\bullet \rightarrow \text{DNA damage}$
10.	NO	Nitrous oxide	NO reductase	$2 \text{ NO} + \text{NAD(P)H} + \text{H}^+ \rightarrow \text{N}_2\text{O} + \text{H}_2\text{O} + \text{NAD(P)}^+$
11.	NO	Nitrate	NO dioxygenase	$\text{Fe}^{3+}(\text{O}_2^-) + \text{NO} \rightarrow \text{Fe}^{3+} + \text{NO}_3^-$

Note: Many of these reactions can occur in the opposite direction, e.g. inhaled NO_2 , an environmental pollutant, is a source of bioactive intravascular nitrite.¹⁸⁷

Experimental studies demonstrating nitric oxide inhibition of ...

Viruses

Numerous preclinical *in vitro* studies have demonstrated that NO sources (stimulated endogenous NO, inorganic and organic nitrates, L-arginine) and PDE5-inhibitors can reduce replication in all seven types of virus as defined in the Baltimore classification (Table 2);²⁵ this includes Class IV viruses (positive-sense RNA viruses) incorporating several coronaviruses^{26–31} including SARS-CoV-2.^{32–34} Most studies showed efficacy although neutral studies were reported for porcine reproductive and respiratory virus (an arterivirus, which is closely related to coronaviruses) and rhinovirus.^{35,36}

Bacteria

Multiple studies have assessed the effect of NO on bacteria and inhibitory effects have been seen across a wide range of gram negative, gram positive and acid-fast bacteria (Table 3). NO sources included L-arginine, NO, nitrite, organic nitrates, and endogenously-generated NO. Multiple mechanisms for efficacy have been reported, as discussed below.

Protozoa

NO sources have been tested on both intracellular and extracellular protozoa (Table 4) with sources involving activated macrophages, sodium nitrite, glyceryl trinitrate, sodium nitroprusside (SNP) and S-nitroso-L-acetylpenicillamine (SNAP).

Fungi and yeasts

The effects of NO on several fungi and yeasts have been studied (Table 5). NO was donated exogenously through stimulating macrophages or as acidified nitrite. *In vitro* experiments demonstrated reduced replication whilst *in vivo* experiments in mice showed reduced infection.

Derivatives of nitric oxide

Whilst endogenous NO derived from eNOS and nNOS is physiologically active *via* its second messenger (cGMP), the antimicrobial effects of NO relate to its toxic effects when present at higher concentrations. Although it is technically challenging to measure free NO concentrations, studies suggest that NO concentrations derived from iNOS are 10–100× higher than those resulting from eNOS/nNOS (Table 6). NO concentrations resulting from exogenous administration lie between those from eNOS/nNOS and iNOS but approximate more closely to those from iNOS than eNOS. Importantly, much antimicrobial NO activity is likely to reflect the effects of derivative molecules rather than NO itself:

Table 2. Studies assessing the effect of nitric oxide on selected viruses ordered by Baltimore class.²⁵

Year	Virus (Baltimore class)	Disease (human unless stated)	NO source	In vitro cell lines	In vivo	Results
	dsDNA (I)					
2020 ¹⁴³	Cytomegalovirus	In compromised immune systems	DETA/NO	MRC-5, ARPE-19		Reduced replication
1993 ¹⁸⁸	Ectromelia	Mousepox	SNAP	293	C57BL/6NCR mice	Reduced replication
1994 ¹⁸⁹	Epstein-Barr	Infectious mononucleosis, Burkitt lymphoma	Constitutive lymphocyte	Human B-lymphocytes		Reduced reactivation
1993 ¹⁸⁸	Herpes simplex-1	Cold sores	SNAP	293	C57BL/6NCR mice	Reduced replication
1993 ¹⁹⁰	Herpes simplex-1	Cold sores	SNAP	RAW 264.7		Reduced replication
2015 ¹²⁶	Human papilloma virus	Anogenital warts	Acidified NaNO ₂		Human	Cure in 31% (active) vs 14% (control)
1999 ²²	Molluscipoxvirus	Molluscum contagiosum	Acidified NaNO ₂		Human	Cure in 75% (active) vs 21% (control)
1993 ¹⁸⁸	Vaccinia	Human "pox"	SNAP	293	C57BL/6NCR mice	Reduced replication
1995 ¹⁹¹	Vaccinia	Human "pox"	L-arg	RAW 264.7		Reduced replication
1995 ¹⁹²	Vaccinia	Human "pox"	iNOS	BSC-40, HeLa G		Reduced replication
	ssDNA (II)					
2017 ¹⁹³	Porcine circovirus-2	Swine multisystemic wasting syndrome	GSNO	PK-15	BALB/c mice	Reduced replication & infection
2009 ¹⁹⁴	Porcine parvovirus	Swine embryonic/foetal death	SNAP, L-arg	PK-15		Reduced replication
	dsRNA (III)					
1996 ¹⁹⁵	Avian (ortho-) reovirus	Avian arthritis, tenosynovitis	LPS-stimulated macrophages	HD11		Reduced replication
	(+)ssRNA (IV)					
1997 ¹⁹⁶	Coxsackievirus (B3)	Pleurodyn timer, myocarditis, pericarditis, and hepatitis	iNOS transfection, SNAP	HeLa		Reduced replication, RNA and protein synthesis
2006 ¹⁹⁷	Dengue virus-2	Viral haemorrhagic fever	SNAP	LLC-MK2 monkey kidney		Reduced RNA and protein synthesis
1999 ¹⁹⁸	Human immunodeficiency virus	Acquired immune deficiency syndrome	SNAP	Human monocytes. U1 cells		Reduced replication in monocytes. Increased replication in U1 cells

Table 2. Continued

Year	Virus (Baltimore class)	Disease (human unless stated)	NO source	In vitro cell lines	In vivo	Results
1997 ¹⁹⁹	Japanese encephalitis virus	Encephalitis	SNAP, IFN- γ activated macrophages	Murine RAW 264.7 and N18 cells		Reduced replication
2005 ²⁰⁰	Mengovirus	Acute fever	Dipyridamole	HeLa or L cells		Reduced replication
1997 ²⁶	Murine coronavirus	Murine hepatitis	SNAP	OBL21a		Reduced replication
1998	Poliovirus	Poliomyelitis	GTN	HeLa, U937		Reduced replication
2010 ³⁵	Porcine reproductive & respiratory virus	Swine reproductive failure, respiratory tract infection	SNAP, NAP	Marc-145 cells		NAP (but not SNAP) inhibited replication
2010 ²⁷	Porcine respiratory coronavirus	Swine reproductive failure, respiratory tract infection	SNAP	STC		Reduced replication
2020 ³⁰	OC43 coronavirus	Cold	NO gas	HCT-8 cells		Reduced replication
1999 ³⁶	Rhinovirus type 23	Common cold	SNAP, SNP, PAPA-NONOate	BEAS-2B cells, MRC-5 cells		No effect on replication
1996 ²⁰¹	Sindbis	Sindbis fever. Murine encephalomyelitis	SNAP, SNP, NOS	N18	BALB/cJ, BALB/cByJ, scid/CB17 mice	Increased cell viability; less death
2004 ²⁸	SARS-CoV-1	SARS	SNAP, SNP	Vero E6		SNAP (not SNP) reduced replication
2004 ³¹	SARS-CoV-1	SARS	NO gas		Human (n=14)	Improved arterial oxygenation, less lung radiological infiltrates
2005 ²⁹	SARS-CoV-1	SARS	SNAP, iNOS	Vero E6		Reduced replication
2020 ³²	SARS-CoV-2	COVID-19	SNAP	Vero E6		Reduced replication, recombinant protease activity
2020 ³³	SARS-CoV-2	COVID-19	Dipyridamole	Vero E6	Human (n=31)	Reduced replication. Clinical improvement, increased L ϕ count
	(-)ssRNA (V)					
1982 ²⁰²	Influenza A 42/72, 1/79, A/fowl plague	'Flu	Dipyridamole		White mice	Reduced replication. Infection prevention
1999 ²⁰³	Influenza A/B	'Flu	SNAP, SNP, SIN-1	Mabin Darby		Reduced replication
2013 ²⁰⁴	Influenza H1N1, H3N2, B HongKong	'Flu	NO gas	MDCK		Reduced infectivity. Inhibition of neuraminidase
2000 ²⁰⁵	Lymphocytic choriomeningitis virus	Meningoencephalitis	IFN- γ		HBV transgenic/iNOS knockout mice	NO mediates antiviral activity of IFN- γ

Table 3. Studies assessing the effect of nitric oxide on selected bacteria.

Year	Bacteria	Disease (human unless stated)	NO source	In vitro	In vivo	Results
	Gram-negative					
2005 ²¹¹	<i>Acinetobacter baumannii</i>	ICU organisms	NO gas (200 ppm)	Bacterial cfu		No viable bacteria by 4.8 (± 1.3) hr
1993 ²¹²	<i>Brucella abortus</i>	Brucellosis	Activated macrophages (IFN- γ)	BALB-c murine J774A.1		Reduced cfu
2003 ¹⁸⁶	<i>Burkholderia pseudomallei</i>	Melioidosis	Activated macrophages (IFN- β)	RAW 264.7 murine macrophages		Reduced intracellular bacteria
1993 ²¹³	<i>Chlamydia trachomatis</i>	Trachoma, pelvic inflammatory disease	Activated McCoy cells (IFN- γ)	Murine fibroblasts		Reduced infectivity
1992 ²¹⁴	<i>Ehrlichia</i>	Ehrlichiosis	Activated macrophages (L-arginine/IFN- γ). SNP	Murine macrophages		No viable bacteria. Dependent on iron (not cGMP)
2005 ²¹¹	<i>Enterobacter aerogenes</i>	ICU organisms	NO gas (200 ppm)	Bacterial cfu		No viable bacteria by 4.8 (± 1.3) hr
2005 ²¹¹	<i>Escherichia coli</i>	ICU organisms	NO gas (200 ppm)	Bacterial cfu		No viable bacteria by 4.8 (± 1.3) hr
1992 ²¹⁵	<i>Francisella tularensis</i>	Tularaemia	Activated macrophages (L-arginine/IFN- γ)	Murine macrophages		Suppressed growth
1998 ¹¹⁸	<i>Helicobacter pylori</i>	Gastritis, gastric/duodenal ulcers	Acidified (pH 2) potassium nitrite	Bacterial cfu		No viable bacteria at KNO ₂ ≥ 500 $\mu\text{mol/L}$
2005 ²¹¹	<i>Klebsiella pneumoniae</i>	ICU organisms	NO gas (200 ppm)	Bacterial cfu		No viable bacteria by 4.8 (± 1.3) hr
1992 ²¹⁶	<i>Legionella</i>	Legionnaires/ Pontiac fever	Activated macrophages (IFN- γ)	RAW 264.7/HL-60		Few viable bacteria
2005 ²¹¹	<i>Pseudomonas aeruginosa</i>	ICU organisms	NO gas (200 ppm)	Bacterial cfu		No viable bacteria by 4.8 (± 1.3) hr
1993 ²¹⁷	<i>Rickettsia</i>	Spotted fever, typhus	Activated macrophages (IFN- γ /TNF- α)	Murine fibroblasts		Reduced infection
1995 ³⁸	<i>Salmonella enterica</i> (Typhimurium)	Typhoid fever	SIN-1, GSNO, (diethylenetriamine-NO)	Suspension		SIN-1: oxygen-dependent cytostasis. GSNO: oxygen-independent cytostasis
2005 ²¹¹	<i>Serratia marcescens</i>	ICU organisms	NO gas (200 ppm)	Bacterial cfu		No viable bacteria by 4.8 (± 1.3) hr

Table 3. Continued

Year	Bacteria	Disease (human unless stated)	NO source	In vitro	In vivo	Results
2005 ²¹¹	<i>Stenotrophomonas maltophilia</i>	ICU organisms	NO gas (200 ppm)	Bacterial cfu		No viable bacteria by 4.8 ($\pm$ 1.3) hr
1992 de Giusti ²¹⁸	<i>Yersinia pestis</i>	Plague (bubonic, pneumonic, septicaemic)	NaNO ₂ , NaNO ₃ , KNO ₃	Pork meat		Reduced growth
	Firmicutes (gram positive)					
1981 ²¹⁹	<i>Bacillus cereus</i>	Gastroenteritis	Nitrosothiols (RSN=O)	Suspension of spores		Inhibition of spore germination
1976 ⁴⁴	<i>Clostridium perfringens</i>	Gastroenteritis	Sodium nitrite			Reduced cfu, G _{AP-DH} and aldolase activity, and free sulphydryl groups
1994 ²²⁰	<i>Listeria</i>	Listeriosis	Sublethal inoculum		C57BL/6 mice	L-NMMA inhibition of NO worsened outcome
2005 ²¹¹	<i>Staphylococcus aureus</i>	ICU organisms	NO gas (200 ppm)	Bacterial cfu		No viable bacteria by 4.8 ($\pm$ 1.3) hr.
2012 ²²¹	<i>Staphylococcus aureus</i>	Wound infection	Probiotic NO gas patch		Ischaemic/infected (<i>S. aureus</i>) full thickness wounds in rabbits	Improved closure.
2013 ¹⁴⁷	<i>Staphylococcus aureus</i>	Experimental biofilms	Glycerol trinitrate	Biofilm		Antimicrobial synergisation with citrate and ethanol
2018 ¹⁴⁸	<i>Staphylococcus aureus</i>	Experimental biofilms	Isosorbide mononitrate	Biofilm		Increased dispersal (conversion of sessile to planktonic cells)
2005 ²¹¹	<i>Streptococci (group B)</i>	ICU organisms	NO gas (200 ppm)	Bacterial cfu		No viable bacteria by 4.8 ($\pm$ 1.3) hr.
	Acid fast					
1991 ²²²	<i>Mycobacterium avium</i>	Atypical respiratory TB	Activated macrophages (TNF)	Human macrophages		Reduced growth
1991 ²²³	<i>Mycobacterium leprae</i>	Leprosy	Activated macrophages (IFN- γ)	Murine macrophages		Reduced <i>M. leprae</i> metabolism
2003 ⁴⁸	<i>Mycobacterium tuberculosis</i>	Respiratory TB	Adjuvant L-arginine		Smear positive TB	Improved outcome (weight, less cough)
2004 ²²⁴	<i>Mycobacterium ulcerans</i>	Buruli skin ulcer	Acidified nitrite (40 mM)	In suspension		Bacteriocidal

cfu: colony forming units; GSNO: S-nitrosoglutathione; IFN- γ : interferon-gamma; MRSA: methicillin resistant *S. aureus*; ppm: parts per million; SIN-1: 3-morpholinodisulphonimine; TB: tuberculosis; TNF: tumour necrosis factor.

Table 4. Studies assessing the effect of nitric oxide on a non-inclusive list of protozoa.

Year	Protozoa	Disease (human unless stated)	NO source	In vitro	In vivo	Results
	Extracellular					
1992 ²²⁵	<i>Entamoeba histolytica</i>	Amoebiasis	Activated macrophages (IFN- γ /LPS)	Murine macrophages		Reduced infection
1992 ²²⁶	<i>Naegleria fowleri</i>	Meningitis	BCG-activated macrophages	Female C57BL/6 mice		Destruction of amoebae
1994 ²²⁷	<i>Opisthorchis</i>	Opisthorchiasis, cholangiocarcinoma				
2013 ²²⁸	<i>Plasmodium berghei</i>	Murine cerebral malaria	TD GTN		Prevention, and adjunctive treatment	Reduced infection, and improved outcome
1989 ²²⁹	<i>Schistosoma mansoni</i>	Schistosomiasis, intestinal	Activated macro-phages (TNF)	Female C57BL/6 mice		Larval cytotoxicity
2017 ²³⁰	<i>Schistosoma japonicum</i>	Schistosomiasis, intestinal	Endogenous from iNOS		Sprague-Dawley rats	Reduced granuloma formation
	Intracellular					
2000 ¹²³	<i>Leishmania major/tropica</i>	Leishmaniasis	Acidified sodium nitrite	BALB/c mice macrophages	Human cutaneous <i>L. tropica</i>	Reduced amastigotes and promastigotes. 28% patients improved, 12% cured.
2000 ¹⁸⁵	<i>Leishmania major</i>	Leishmaniasis	Activated macrophages (IFN- α / β)	CD1/C57BL/6 mice macrophages		Reduced intracellular parasites
2016 ²³¹	<i>Leishmania</i> spp.	Leishmaniasis	SNP	BALB/c mice macrophages		Reduced amastigotes and promastigotes
1990 ²³²	<i>Toxoplasma gondii</i>	Toxoplasmosis	Activated macrophages (IFN- γ /LPS)	Murine macrophages		Reduced growth
1996 ²³³	<i>Toxoplasma gondii</i> (ME49)	Toxoplasmosis	Spleen cells		C57BL/6 mice	Increased ocular inflammation with aminoguanidine
1992 ¹⁶⁹	<i>Trypanosoma brucei gambiense/brucei</i>	African trypanosomiasis (sleeping sickness)	Activated macrophages (BCG-infected mice or IFN- γ /LPS)	Murine macrophages	BCG-infected mice	No proliferation (cytostasis). Reduced parasitaemia/prolonged survival
1994 ¹⁷⁰	<i>Trypanosoma brucei</i>	African trypanosomiasis (sleeping sickness)	SNAP. Activated macrophages (IFN- γ)	Murine peritoneal macrophages	C3H.He mice	<i>In vitro</i> : NO inhibits proliferation. <i>In vivo</i> : NO reduced protozoa T-cell proliferative responses

BCG: bacillus Calmette-Guerin; GTN: glycyl trinitrate; IFN- γ : interferon-gamma; iNOS: inducible nitric oxide synthase; LPS: lipopolysaccharide; SNAP: S-nitroso-L-acetylpenicillamine; SNP: sodium nitroprusside; TD: transdermal; TNF: tumour necrosis factor.

Table 5. Studies assessing the effect of nitric oxide on a non-inclusive list of fungi and yeasts.

Year	Fungi/Yeasts	Disease (human unless stated)	NO source	In vitro	In vivo	Results
	Fungi					
1999 ²³⁴	<i>Aspergillus fumigatus</i>	Aspergillosis	Activated macro-phages (IFN- γ)	Rat alveolar macrophages		Reduced infection
1998 ¹²¹	<i>Epidermophyton floccosum</i>	Tinea pedis	Acidified NaNO ₂		Human (n=35)	Cure in 81% (active) vs 31% (control)
1994 ²³⁵	<i>Histoplasma capsulatum</i>	Histoplasmosis ('flu-like')	IFN- γ /LPS activated macrophages	C57BL/6 mice		Reduced infection
1999 ²³⁶	<i>Pneumocystis carinii</i>	Pneumonia	IFN- γ activated macrophages via L-arginine	Sprague Dawley rats		Killed <i>P. carinii</i>
1998 ¹²¹	<i>Trichophyton rubrum</i> , <i>T. interdigitale</i>	Tinea pedis	Acidified NaNO ₂		Human (n=35)	Cure in 81% (active) vs 31% (control)
	Yeasts					
1993 ²³⁷	<i>Candida albicans</i>	Candidiasis (oropharyngeal, vulvovaginal), candidaemia	Murine macrophages	<i>C. albicans</i> infection	Mice	Reduced infection
1991 ²³⁸	<i>Cryptococcus neoformans</i>	Cryptococcosis (pneumonia, meningitis, encephalitis)	Acidified NaNO ₂	<i>C. neoformans</i> culture		Reduced replication
1999 ²³⁴	<i>Cryptococcus neoformans</i>	Cryptococcosis	Activated macro-phages (IFN- γ)	Rat alveolar macrophages		Reduced infection
2018 ²³⁹	Dermatophytes	Onychomycosis, tinea pedis	NVN1000	Macrodilution broth test		78-99% kill

IFN- γ : interferon-gamma; LPS: lipopolysaccharide; NaNO₂: sodium nitrite.

Table 6. Nitric oxide concentrations following endogenous synthesis by nitric oxide synthase, and exogenous NO donors.

NO	eNOS/nNOS	iNOS	Exogenous NO
Source	Endothelium, neurones	Intracellular, e.g. macrophages	Exogenous
Role	Cell signalling	Microbial killing	Vasodilation, antiplatelet
Synthesis	Constitutive, intermittent ("dripping tap" ¹⁷), calcium-dependent, feedback controlled	Inducible, continuous ("fire hose" ¹⁷), calcium-independent/cytokine-microbial dependent. Part of innate immunity	
Concentration	0.1-5 nM ²⁴⁰	>10 μ M ²⁴⁰	SNP, 52 nM ²⁴¹
Targets	sGC (CcOX)	Aconitase, NADH dehydrogenase, succinate dehydrogenase, metalloenzymes, ribonucleotide reductase, DNA	sGC
Effects	Reversible	Irreversible. Nitrosation, nitration, oxidation.	Reversible

CcOX: cytochrome c oxidase (Complex IV); sGC: soluble guanylate cyclase; SNP: sodium nitroprusside.

- Nitric oxide (NO[•]). In general, bacteria deficient in low molecular weight thiols such as glutathione (*e.g.* *Staphylococci* spp.) are sensitive to attack by NO whereas those with high thiol concentrations are resistant to NO.
- Peroxynitrite (OONO⁻, Table 1.3). The reaction between NO and superoxide means that NO synergises with the respiratory burst, another antimicrobial system present in phagocytic cells. Experimentally, this synergism can be inhibited with the addition of superoxide dismutase which converts superoxide into molecular oxygen and hydrogen peroxide (Table 1.4).
- Peroxynitrous acid (ONOOH, Table 1.5), *e.g.* toxic to *Escherichia coli*.³⁷
- Nitrogen dioxide (NO₂, Table 1.6), *e.g.* toxic to *E. coli*.³⁷
- Dinitrogen trioxide (N₂O₃, Table 1.7).
- Dinitrogen tetroxide (N₂O₄, Table 1.8).
- S-nitrosothiols (RSNO, *e.g.* S-nitrosoglutathione), *e.g.* toxic to *E. coli* and *Salmonella enterica* serovar typhimurium.³⁸ RSNO reacts with protein sulphhydryl groups changing their function. Thiol concentrations do not appear to determine sensitivity to peroxynitrite and S-nitrosothiols.
- Dinitrosyl-iron ((2 RS)-Fe-(2 NO)). The reaction of NO with iron or iron-sulphur molecules can: inactivate enzymes such as aconitase (which converts citrate to isocitrate in the citric acid cycle), ribonucleotide reductase and ubiquinone reductase; increase free ferrous (Fe²⁺) which causes oxidative damage; and deplete iron stores.
- RNOS (especially auto-oxidised products of NO).

Since these molecules differ in their stability, reactivity, location and cellular diffusivity, the overall effect of NO will depend on the molecular species involved and its location.

Cellular and other targets of nitric oxide

The targets for NO and associated reactive nitrogen species are multitudinous:

- DNA, through deamination of adenine, cytosine and guanine;³⁹ cross-linking; breakage of strands; inhibition of DNA repair enzymes such as DNA alkyl transferases (and so preventing transfer of the guanine alkyl group to

protein); and disruption of DNA replication by inhibition of ribonucleotide reductase,⁴⁰ as in *S. enterica* and vaccinia virus.

- RNA, through disruption of RNA replication by inhibition of viral ribonucleotide reductase.
- Inhibition of mitochondrial function, specifically through inactivation of iron-sulphur complexes within respiratory chain enzymes.⁴¹
- Protein modification at cysteine, methionine, phenylalanine, tryptophan and tyrosine residues, *e.g.* by RNOS. Such protein effects will reduce enzyme activity, as seen for DNA, proteases⁴² and mitochondrial function, as in Cocksackievirus.⁴²
- Limit late protein synthesis, *e.g.* through posttranslational modification of viral proteases. (Early protein translation/synthesis is not typically affected.)
- Induction of lipid peroxidation.
- Limit glutaminolysis by shuttling glutamine to glutathione synthesis, as in cytomegalovirus.⁴³
- Interaction with sulfhydryl-containing constituents of the bacterial cell.⁴⁴
- Disrupt zinc homeostasis, as in *S. enterica*.⁴⁵
- Limit virion assembly/particle formation.
- Reduce bacterial adhesion to NO-releasing surfaces.⁴⁶

Nitric oxide may also play an augmenting role as an antimicrobial agent. Examples include the adjuvant roles of NO when given with type I interferons in the treatment of DNA viruses⁴⁷ and L-arginine when given with conventional chemotherapy in smear-positive TB.⁴⁸

In addition, NO's vasculo-active effects are likely to be beneficial in preventing infection and its severity, with NO:

- Reversing endothelial dysfunction and so potentially reducing endotheliitis,⁹ as occurs in COVID-19.^{7,8}
- Reducing leucocyte function (*e.g.* adhesion, chemotaxis, phagocytosis);² COVID-19 is associated with increased phagocyte counts.^{8,49}
- Reducing platelet activation and platelet-leucocyte conjugation and so reducing micro- and macro-thrombosis, as seen in COVID-19.^{8,50}
- Improving organ blood flow and perfusion through smooth muscle relaxation and vasodilation and so likely reversing infection-related vasoconstriction as seen in COVID-19,⁸ including in the pulmonary circulation.⁵¹

These actions of NO are all mediated *via* the second messenger cGMP.

Antimicrobial production of nitric oxide

NO is produced by some bacteria, archaea and yeasts *via* several pathways including denitrification of nitrate to nitrite and then to NO⁵² and oxidation of L-arginine to NO and L-citrulline as catalysed by a bacterial nitric oxide synthase (bNOS), a process that can be inhibited by NOS inhibitors.⁵³ Whilst eukaryotic NOS contains both catalytic and reductase domains, prokaryotic bNOS lacks the latter relying instead on other cellular reductases to generate NO; the one exception to this is the bNOS present in *Sorangium cellulosum* which does include a reductase module.

In contrast to the signalling role of NO in mammals, NO synthesis in bacteria has multiple functions which vary between antimicrobial species:^{54–57}

- Protection against oxidative stress with NO limiting thiol reduction and so the formation of hydroxyl radicals (*Bacillus anthracis/subtilis*, *Staphylococcus aureus*⁵⁴) (Table 1.9).
- Protection against oxidative stress with NO activating catalase (*B. subtilis*). Such defence will limit damage from phagocytic respiratory bursts.⁵⁴
- Protection against oxidative stress by reducing endogenous NO synthesis and increasing the expression of NO dioxygenase to detoxify NO (*Candida albicans*).⁵⁶
- Biosynthesis of toxins, e.g. thaxtomins (a phytotoxin) interfere with potato plant wall synthesis (*Streptomyces turgidiscabies*).⁵⁴
- Activation of aerobic and nitrate respiration to optimise growth (*S. aureus*).^{57,58}
- Protection against antimicrobial agents including amoxycillin, cefuroxime, gentamicin and novobiocin (*B. anthracis/cereus/thuringiensis/weihenstephanensis*, *S. aureus*),⁵⁵ and azoles (*Candida albicans*).⁵⁶

The production by some microbes of endogenous NO to protect against oxidative stress is ironic since hosts are using NO to try to destroy the microbe!

Resistance to nitric oxide

Microbial resistance to antibiotics is an increasingly common problem and has left some bacteria with few treatment options, e.g. drug-resistant *Neisseria gonorrhoeae*. Hence, it is vital to consider whether resistance to NO is innate in some microbes or can be acquired. As already highlighted, some microbes have an intrinsic ability to produce their own NO and so attenuate the effects of oxidative stress (e.g. *B. anthracis/subtilis*, *C. albicans*, *S. aureus*^{54,56}), activate aerobic respiration (*S. aureus*⁵⁷) or protect against antimicrobial agents (*B. anthracis/cereus/thuringiensis/weihenstephanensis*, *C. albicans*, *S. aureus*^{55,56}).

Microbes may also have mechanisms for deactivating NO. One mechanism is via a NO reductase which reduces NO to nitrous oxide and then nitrogen, e.g. as occurs in fungi⁵⁹ (Table 1.10). Bacteria have different NO reductases but similarly produce nitrous oxide,⁵⁹ as seen in *Pseudomonas aeruginosa*.⁵² Loss-of-function mutations in NO reductase may be lethal, possibly because intracellular NO concentrations rise to toxic levels.

A second mechanism for detoxifying NO is via NO dioxygenase oxidation to nitrate (Table 1.11). The pre-eminent NO dioxygenase is flavohaemoglobin,⁶⁰ as present in bacteria (e.g. *Salmonella enterica*, *S. aureus*, *Vibrio cholerae*, *Yersinia pestis*,^{20,61,62}) and yeasts. A related haemoglobin, truncated haemoglobin, detoxifies NO in mycobacteria. Of note, *Mycobacterium leprae* has undergone reductive genome evolution losing more than 2,000 genes, including some that protect against RNOS; as a result, *M. leprae* has fewer defences against NO than *Mycobacterium tuberculosis*.⁶³ Bacterial lactate dehydrogenase also detoxifies NO, as seen in *S. aureus*.²⁰ Importantly, these detoxifying enzymes only cope with low levels of NO and are not protective against high NO levels.

As a result, microbes show differing sensitivities to NO, as seen for common airways pathogens where sensitivity was ranked (sensitivity most to least): *P. aeruginosa* ~ *C. albicans* > *S. aureus* > *Klebsiella pneumoniae* ~ *Staphylococcus epidermidis*.⁶⁴

However, there is little evidence that bacteria can acquire *de novo* resistance to NO, as confirmed in experiments on strains of *E. coli*, *P. aeruginosa*, *S. aureus* and *Staphylococcus epidermidis*.⁶⁵ This property is unsurprising since NO has multiple mechanisms for antimicrobial activity and these are likely to be invoked orders of magnitude faster than any microbe can process metabolically, especially if protein synthesis is required. Equally, the main mechanisms for antibiotic resistance (drug inactivation, altered binding sites or metabolism and reduced drug permeability) are unlikely to be relevant to many NO sources. Whether viruses, protozoa and fungi can develop resistance to NO remains unclear.

Administering nitric oxide, donors and related compounds

L-arginine

In the presence of NOS, administration of L-arginine may enhance NO synthesis (Table 7) although intracellular L-arginine levels are not normally rate limiting and so administration may not have physiological effects.⁶⁶ Although oral

Table 7. Nitric oxide sources.

Intervention	Example	Administration	Licensed for use in (BNF)	Antimicrobial effects: target (disease)
L-arginine	Dietary: meat	Oral	N/A	None reported
	Powder		N/A	Mycobacteria tuberculosis (pulmonary tuberculosis) ⁴⁸
	Liquid	Intravenous	N/A	None reported
Inorganic nitrite	Acidified sodium nitrite (NaNO ₂) cream	Topical		<i>Burkholderia cepacia</i> , dermatophytes (tinea pedis), ¹²¹ pox virus (molluscum contagiosum), ¹²² Leishmaniasis, ¹²³ <i>Mycobacterium ulcerans</i> (Buruli ulcer), ¹²⁴ human papilloma virus (anogenital warts), ¹²⁶ <i>Propionibacterium acnes</i> , <i>P. aeruginosa</i> , <i>S. aureus</i> (including MRSA), ^{25, 105}
		Oral	N/A	Food preservation; ¹⁴⁵ <i>Clostridium botulinum</i>
		Intravenous	Cyanide poisoning (given with sodium thiosulfate) ¹⁴⁵	None reported
Inorganic nitrate	Silver nitrate	Topical	Common wart (human papilloma virus)	Human papilloma virus (Common wart). ¹²⁷
	Dietary: beetroot, celery, rocket, spinach	Oral	N/A	<i>Lactobacillus</i> , <i>Streptococcus</i> (tooth decay), <i>C. albicans</i> (oral infection), <i>Campylobacter</i> , <i>E. coli</i> O157, <i>Salmonella enterica</i> (Typhimurium), <i>Shigella sonnei</i> , <i>Yersinia enterocolitica</i> (gastroenteritis) ¹¹³
Organic nitrate	Glyceryl trinitrate (GTN)	Topical patch	Prophylaxis of angina and phlebitis	Malaria (murine cerebral malaria). ²²⁸ Non-specific infections (presenting as stroke mimics). ¹⁵⁰
		Ointment	Treatment of anal fissure	None reported
		Sublingual	Prophylaxis-treatment of angina	None reported
		Intravenous	Hypertension/myocardial ischaemia after cardiac surgery. Congestive heart failure. Unstable angina	<i>E. coli</i> , <i>P. Aeruginosa</i> , <i>S. aureus</i> in solution. ²⁴² <i>S. aureus</i> , MRSE, <i>P. aeruginosa</i> , <i>C. albicans</i> in biofilms ¹⁴⁷
	Isosorbide dinitrate (ISDN)	Oral	Prophylaxis/treatment of angina. Left ventricular failure	None reported
		Sublingual	Prophylaxis/treatment of angina	None reported
		Intravenous	Prophylaxis/treatment of angina. Left ventricular failure	None reported
	Isosorbide mononitrate (ISMN)	Oral	Prophylaxis of angina. Adjunct in congestive heart failure.	<i>S. aureus</i> in biofilms ¹⁴⁸

Table 7. Continued

Intervention	Example	Administration	Licensed for use in (BNF)	Antimicrobial effects: target (disease)
Spontaneous nitric oxide donors	Sodium nitroprusside (SNP)	Intravenous	Hypertensive emergencies. Controlled hypotension. Acute/chronic heart failure	<i>E. coli</i> , <i>P. aeruginosa</i> , <i>S. aureus</i> in solution. ²⁴² <i>Bacillus licheniformis</i> , <i>Candida albicans</i> , <i>Escherichia coli</i> BW20767, <i>Fusobacterium nucleatum</i> , <i>Serratia marcescens</i> MG1, <i>S. epidermidis</i> , <i>Vibrio cholerae</i> 92A1552. ²⁴³ <i>Leishmania</i> spp. ²³¹
Nitric oxide	Nitric oxide (NO) gas	Gas	(Neonatal pulmonary hypertension)	<i>E. coli</i> , <i>P. aeruginosa</i> , <i>S. aureus</i> . ²⁴⁴ SARS-CoV-2 (ongoing trials: NCT04290871, NCT04305457, NCT04312243).
		Probiotic patch	N/A	<i>E. coli</i> , <i>S. aureus</i> , MRSA, <i>P. aeruginosa</i> , <i>T. mentagrophytes</i> , <i>T. rubrum</i> . ^{221,245}
		NO releasing solution	N/A (in development)	<i>Propionibacterium acnes</i> , <i>T. mentagrophytes</i> , <i>T. rubrum</i> . SARS-CoV-2 (ongoing trial: NCT04337918)
PDE5 inhibitor	Dipyridamole	Oral	Post-stroke prophylaxis.	Picornaviridae, Togaviridae, Orthomyxoviridae, Paramyxoviridae, Herpetoviridae and Poxviridae. ²⁴⁶ Mengovirus. ²⁰⁰ SARS-CoV-2 (COVID-19 clinical trial). ³³
	Sildenafil	Oral	Erectile dysfunction, pulmonary arterial hypertension	Adenovirus, Chikungunya, Cytomegalovirus, Dengue, Enterovirus 71, Influenza virus, Measles, Mumps, Rabies, Respiratory syncytial virus, Rubella, West Nile, Yellow Fever; Methicillin-resistant <i>Staphylococcus epidermidis</i> . ^{247,248} SARS-CoV-2 (ongoing trial: NCT04304313).

BNF: British National Formulary; N/A: not applicable.

preparations of L-arginine are commercially available, consumption of high doses is associated with profuse diarrhoea (P Bath, personal observation).

Inhaled nitric oxide

Gaseous NO may be inhaled with the aim of improving pulmonary haemodynamics and killing microbes. Multiple trials are underway for COVID-19 prevention and treatment (Table 9). NO may also be created in real time by combining sodium nitrite and citric acid and administering this either as a nasal spray (for local therapy) or *via* nebuliser (for combined nasal and bronchial therapy).

Organic nitrates

Organic nitrates such as GTN, isosorbide dinitrate (ISDN) and isosorbide mononitrate (ISMN) are widely used in vascular medicine for the prevention and treatment of angina, treatment of chest pain in unstable angina and myocardial infarction, treatment of severe heart failure, and blood pressure lowering after cardiac surgery and in acute stroke (Table 7). There is increasing concern that chronic use of organic nitrates may cause major adverse cardiac events and death,⁶⁷ reduce daily activity,⁶⁸ and not improve quality of life or exercise capacity.⁶⁸ Potential explanations include the development of tolerance, and induction of endothelial dysfunction and cell damage through oxidative stress, *e.g.* production of free radicals/peroxynitrite.^{69,70}

Importantly, organic nitrates only release NO in cells and tissues expressing mitochondrial aldehyde dehydrogenase-2.⁷¹ For example, SNP and SIN-1 inhibit monocyte chemotaxis whilst organic nitrates (ISDN, GTN and molsidomine) do not;⁷² this contrasts with smooth muscle cells which vasodilate with all five agents. Since aldehyde dehydrogenase-2 suffers from use-inactivation, nitrate tolerance (tachyphylaxis) and endothelial dysfunction develops⁷⁰ and bioconversion only restarts following a nitrate-free period. Several *in vitro* studies have demonstrated the potential antimicrobial effects of organic nitrates (Table 7). Other non-organic nitrates include pentaerythritol tetranitrate and erythrityl tetranitrate.

Therapeutic inorganic nitrite and nitrate

Therapeutic use of inorganic nitrite is limited with intravenous administration used in cyanide poisoning (British National Formulary). Topical acidified sodium nitrite has been shown to reduce cutaneous infections secondary to a variety of viruses and bacteria although its general use is probably limited by skin irritation and erythema (Table 7).

Dietary inorganic nitrate

NO may also be produced from dietary inorganic nitrate, as is present in high concentrations in green leafy and some root vegetables, *e.g.* spinach, lettuce, rocket, beetroot, celery, fennel, radish and Chinese cabbage.⁷³ Nitrate is absorbed from the proximal gastrointestinal tract, excreted by salivary glands, reduced to nitrite by oral bacteria and then absorbed in the gastrointestinal tract. A number of bacterial species situated on the dorsal surface of the tongue perform this conversion *via* nitrate reductases.⁷⁴ (In the absence of oxygen, nitrate and nitrite are commonly used by bacteria as terminal electron acceptors for respiration.⁷⁵) Through this symbiotic relationship, the mammalian host provides the nutrients and the environment in return for nitrite production by bacteria.⁷⁶

Absorbed and circulating nitrite is then further reduced to NO, a process that is enhanced in hypoxic or acidic conditions and by multiple mechanisms including deoxyhaemoglobin, deoxymyoglobin, xanthine oxidoreductase and endothelial nitric oxide synthase.^{77,78} As such, most effects of dietary nitrate will be vascular and perivascular. The beneficial vascular protective effects of vegetable consumption are very clear epidemiologically, as present in the classical Japanese diet,⁷⁹ the Dietary Approaches to Stop Hypertension (DASH) diet,⁸⁰ and the Mediterranean diet.^{81,82} Further, vegetable-derived nitrate may reduce the risk of gastrointestinal cancer.^{73,83,84} The benefit on cancer is at variance with oral consumption of nitrite. Although nitrite is not carcinogenic *per se*, the processing and cooking of nitrite-cured meat can form carcinogens such as N-nitroso compounds and heterocyclic aromatic amines. In contrast, carcinogens are not formed when eating raw vegetable-derived nitrate. A recent meta-analysis showed an increased risk gastric cancer with oral nitrite but reduced risk with oral nitrate.⁸⁵ Dietary nitrate is known to modify the oral and gastric biome (Table 7).

High dietary intake of nitrate is associated with many mechanisms that may have beneficial vascular, and potentially, antimicrobial effects. Experimentally, beetroot juice is often used as a potent source of dietary nitrate since dosing can be controlled and a nitrate-free placebo version is available for use in randomised controlled trials. Studies have shown that beetroot juice increases plasma nitrate and nitrite concentrations,^{86,87} that most vascular effects are mediated *via* the second messenger cGMP,⁸⁷ tolerance does not develop (unlike with organic nitrates)⁷³ and inorganic nitrate does not lead to free radical formation. In clinical studies, beetroot juice has been given over weeks and months^{86–91} and has been shown to have multiple effects with improved exercise performance (hence use by elite athletes)⁹²; improved cognitive

performance in older people⁹²; vasodilation with reduced blood pressure^{89,90,92–95}; antiplatelet and anti-leucocyte effects and reduced platelet-leucocyte conjugation^{86,89}; improved endothelial function; reduced left ventricular volume;⁹¹ improved metabolic profile; and improved oral health.⁸⁹ Beyond anti-inflammatory effects on blood cells, nitrite or nitrate reduce soluble pro-inflammatory factors including C-reactive protein, chemokine (C-X-C motif) ligand-1/2, endothelin-1, interleukins-1 β /6/10/12p70, interferon- γ , monocyte chemoattractant protein and tissue necrosis factor- α .⁹⁶ Dietary nitrate has profound metabolic effects and appears to have the potential for reversing the metabolic syndrome and have anti-diabetic effects.⁹⁷ Overall, the pharmacological effects of beetroot juice have been demonstrated in younger and older people, and in people with cardiovascular disease, *e.g.* diabetes, obesity, hypertension, hypercholesterolaemia, heart failure and stroke.⁹⁸ Importantly, inorganic nitrate (given as beetroot juice) may be taken by pregnant women.⁹⁹ Experimentally, watermelon juice and chard gel may be used as an alternative source of dietary nitrate.^{100,101}

Phosphodiesterase-5 inhibitors

PDE5-inhibitors, such as dipyridamole and sildenafil, enhance the physiological effects of NO as mediated by cGMP. Whether these agents should have antimicrobial effects is unclear since they do not enhance NO levels *per se*; nevertheless, both drugs have exhibited antimicrobial activity (Table 7) and are being tested in COVID-19 trials (Table 9).^{102,103}

Stimulation of endogenous nitric oxide-dependent nitric oxide production

Endogenous NO production may also be stimulated externally. First, nasal breathing promotes the production of NO from the paranasal sinuses and this has bronchodilatory, vasodilatory and potential antimicrobial activities.¹⁰⁴ This natural defence mechanism may be attenuated with mouth breathing, as occurs with increasing age and obesity. Second, ultraviolet radiation (UVA and UVB) stimulates the release of NO from both keratinocytes and melanocytes; NO has multiple effects including attenuation of free radical damage, melanogenesis, blood pressure lowering¹⁰⁵ and potentially protection against skin infections.

Novel nitric oxide agents

Recent research has focussed on the development of new antimicrobial NO delivery systems and some examples are listed:

- NO microspheres, *e.g.* biodegradable poly (lactic-co-glycolic acid) spheres loaded with S-nitroso-N-acetyl-D-penicillamine.¹⁰⁶
- NO-releasing nanoparticles, with activity against *Acinetobacter baumannii*, *C. albicans*, *Enterococcus faecalis*, *E. coli*, *K. pneumoniae*, *P. aeruginosa*, *S. aureus* (MRSA), *S. epidermidis*, *Trichophyton mentagrophytes*.^{105,107}
- Modified chitosan, *e.g.* against *Trypanosoma cruzi*,¹⁰⁸ *E. coli*, *S. aureus*, *Streptococcus mutans*.¹⁰⁹
- NO–metal complexes (zeolites), with activity against *B. subtilis*, *Clostridium difficile*, *E. coli*, *P. aeruginosa*, *S. aureus* (including MRSA).¹⁰⁵
- NONOates (diazoniumdiolates), *e.g.* with activity against *C. albicans*, *E. coli*.^{105,110}
- NO coating of medical device surfaces and tubing,^{111,112} *e.g.* using S-nitroso-N-acetyl-D-penicillamine to kill *Staphylococcus aureus* and *P. aeruginosa*.

NO sources can also be categorised by whether administration is local (*e.g.* cutaneous nitrite or intranasal preparations), systemic (*e.g.* dietary nitrate or L-arginine, oral isosorbide or sildenafil, sublingual GTN, intravenous GTN or SNP) or mixed local and systemic (transdermal GTN). Local administration allows high and potentially lethal concentrations of NO to be achieved without unwanted systemic effects. Intravenous formulations might allow for systemic infections to be treated.

Relevance of *in vitro* studies to preclinical and clinical studies

Most microbial studies presented above and in Tables 2–5 were performed *in vitro* and involved either inducing the L-arginine/NO pathway with cytokines (*e.g.* interferon gamma [IFN- γ] and/or lipopolysaccharide [LPS]) or with NO sources (such as NO gas, nitrite, 3-morpholiniosydnonimine, S-nitroso-L-acetylpenicillamine or sodium nitroprusside). However, the inhibitory effect of NO on microbes *in vitro* does not represent the complex biochemical environment that they face *in vivo* including the presence of NO derivatives such as peroxynitrite, microbial production of NO, microbial

resistance to NO and excess NO synthesis. Nevertheless, there are many *ex vivo* and clinical examples where NO has been effective. These issues are now discussed.

Nitric oxide for clinical infections

Oral health and gastrointestinal infections

As already highlighted, oral bacteria (*e.g. Corynebacterium pseudodiphtheriticum, Fusobacterium nucleatum, Nocardia* spp., *Prevotella melaninogenica, S. aureus, S. epidermidis, Veillonella* spp.) are vital for the reduction of salivary nitrate to nitrite as part of the entero-salivary circulation; nitrite is further reduced to NO.¹¹³ This represents a symbiotic relationship between bacteria and the mammalian host; the host provides the nutrients and the environment in return for nitrite production,⁷⁶ as in the absence of oxygen, nitrate and nitrite are commonly used by such bacteria as terminal electron acceptors for respiration.⁷⁵

Oral consumption of nitrate and the resulting increase in nitrite in the oro-pharynx leads to salivary alkalinisation (pH ~7.0 to 7.5)¹¹⁴ and so reduction in detrimental bacteria and caries.⁷⁴ Similarly, nitrate supplementation was associated with increased oral *Rothia* spp. and *Neisseria* spp. and diminished oral *Prevotella* spp. and *Veillonella* spp.; in parallel, plasma nitrite levels rose and systemic blood pressure fell.¹¹⁵ Salivary nitrite production is related to the abundance of oral-nitrate-reducing bacteria.¹¹⁶ In contrast, bacteria and yeast, in particular *Lactobacillus* spp., *Streptococcus* spp. and *C. albicans*, are key to the development of dental caries through the production of acid. Equally, antibiotics that kill nitrate-reductase-containing bacteria inhibit oral nitrite production and so increase the risk of oral thrush.¹¹⁷ Acidified nitrite has antibacterial activity against *Helicobacter pylori* *in vitro*,¹¹⁸ an experiment that likely mimics the scenario seen by these bacteria in the stomach after a nitrate/nitrite-rich meal.

Cutaneous infections

The skin is a potent source of nitric oxide and production is increased with exposure to sunlight (specifically ultraviolet radiation) sufficient to lower blood pressure.^{119,120} Hence, skin-derived NO may form a natural dermatological antimicrobial defence. Numerous studies have demonstrated that topical acidified sodium nitrite reduces cutaneous infections due to a variety of viruses and bacteria (Table 7) although prophylaxis had to be continued in some cases since NO suppressed replication without necessarily being viro-toxic.^{121–126} Inorganic nitrate has been used for the treatment of human papilloma virus.¹²⁷ Phase II clinical trials have found that acidified nitrite in cream reduced *Leishmania major/tropica* amastigotes and promastigotes with a reduction in cutaneous leishmaniasis¹²³ and increased cure rates in tinea pedis.¹²¹ Novel NO agents are in development to treat skin conditions (Table 8).

Respiratory infections

In animal and human experiments, NO substrate (L-arginine) and a NO donor (SNP) has been shown to improve the mucociliary activity of the upper respiratory tract¹²⁸ suggesting a modulatory role for NO in nasal barrier function and clearance. Novel NO agents building on this observation are in development (Table 8):

Endogenous NO has potent pulmonary haemodynamic and bronchodilator effects physiologically. The importance of endogenous NO in preventing infection is apparent experimentally where inhibition of NO results in increased susceptibility to microbes including *Leishmania* spp., *Mycobacterium* spp. and *Plasmodium* spp.¹²⁹ Similarly, NO sources are used therapeutically, for example sildenafil in the management of pulmonary hypertension (Table 7). In respect of airway epithelial cells, nitrite reduced *P. aeruginosa* biofilm growth.¹³⁰ In infection, NO reduces pulmonary vascular resistance and intrapulmonary shunt, and improves oxygen partial pressure in patients with acute severe pneumonia.¹³¹ More specifically, inhaled NO improves arterial oxygenation enabling a reduction in inspired oxygen therapy and airway pressure support, and reduces lung infiltrates, in patients with severe acute respiratory syndrome (SARS).³¹ These findings continue after termination of NO therapy suggesting that NO has both pulmonary vasodilator and anti-SARS effects. Small uncontrolled clinical studies have suggested that iNO may be beneficial in COVID-19.^{132–136} iNO and novel NO agents are in development, primarily for COVID-19 at present (Table 8, 9).

Dipyridamole, a phosphodiesterase 5 inhibitor, may also have similar beneficial effects in severe COVID-19.³³ A phase II clinical trial found that L-arginine might have beneficial effects when given on top of conventional therapy for tuberculosis (Table 7).⁴⁸

Urinary tract infections

There may also be a role for dietary nitrate/inorganic nitrite in the prevention and treatment of urinary tract infections. Many of the lower urinary tract opportunistic organisms (*e.g. E. coli*) possess nitrate reductases, this forming the basis of urine dipstick detection of nitrite. In acidic urine conditions, nitrite is reduced to NO with toxicity to bacteria; for example, transferring nitrite-rich urine containing *E. coli* to a more acidic environment (*e.g. pH 5.5*) dose-dependently inhibited

Table 8. Examples of commercial development of novel nitric oxide donors/agents with efficacy against target disease and microbes (where relevant, last searched 15 March 2021).

	Target organism/disease	Commercial company
NO gas for inhalation		Beyond Air
NO gas for inhalation		INOMax
NO-releasing solution for nebulisation (sodium nitrite and citric acid)	COVID-19	30 Technology
NO released from acidified nitrite via a semi-permeable membrane	Cutaneous <i>S. aureus</i> , <i>E. coli</i> ²⁴⁹	
NO macromolecular scaffolds, ^{46,250} e.g. NO-releasing cyclodextrins ²⁵¹	<i>P. aeruginosa</i>	Vast Therapeutics
Polymer-based chronic NO delivery systems e.g. for treatment of biofilms, ²⁵²	Cutaneous viruses (human papilloma virus, molluscipoxvirus), dermatophytes (<i>Epidermophyton floccosum</i> , <i>Fusarium solani</i> , <i>T. rubrum</i> , <i>T. mentagrophytes</i>) or yeast (<i>Candida albicans/tropicalis</i> , <i>Malassezia furfur</i>) ²³⁹	Novan
NO-releasing solution/gel (NORS2791) NO-releasing solution (NORS6491) NO-releasing nasal spray (NORS1002) NO-releasing nasal lavage (NORS4002)	Acne (<i>Propionibacterium</i>), fungal nail infections/onychomycosis (<i>T. rubrum</i> , <i>T. interdigitale</i>) Athlete's foot (<i>T. rubrum</i> and <i>T. mentagrophyte</i>) Cold, 'flu, COVID-19 Sinusitis	SaNOtize
NO-stimulating nasal spray (GLS-1200)		GeneOne Life Science
Nitric oxide generating lozenges (sodium nitrite)	COVID-19	Nitric Oxide innovations
NO-generating probiotic patches, e.g. based on Lactobacilli conversion of glucose to lactic acid, and acidification of sodium nitrite ^{221,245}	<i>S. aureus</i>	McGill University, Canada
Nitroreductase-activated release of NO, e.g. by O ² -(4-Nitrobenzyl) diazeniumdiolate ²⁵³ or nitroaromatic-protected piperazine diazeniumdiolate ²⁵⁴	<i>E. coli</i>	Indian Institute of Science Education and research, Pune, India Colorado State University, Fort Collins, USA

bacterial growth,¹³⁷ an effect potentiated by vitamin C. The antibacterial potency is comparable to conventional antibiotics such as trimethoprim and nitrofurantoin.

This approach has been tested by filling urinary catheter retention balloons with nitrite and ascorbic acid, resulting in measurable amounts of NO outside the membrane and effectively killing two strains of *E. coli* in the surrounding urine.¹³⁸ A similar approach found decreased bacterial counts and prevented biofilm formation by *P. aeruginosa*, *K. pneumoniae*, and *Enterobacter cloacae* (but not *E. coli* or *S. aureus*).¹³⁹

Last, instillation of bacillus Calmette-Guerin (BCG, an attenuated strain of *Mycobacterium bovis*) into the bladder is used for the treatment of superficial/non-muscle invasive bladder cancer and carcinoma *in situ*. BCG induces long-term increases in NOS activity in urothelial cells^{140,141} and the formed NO is toxic to the malignant cells. The use of BCG to provide non-specific protection against SARS-CoV-2 is to be tested^{142,143} although vaccination in infancy does not appear to protect against COVID-19 in adults.¹⁴⁴

Other infections

Nitrate (usually KNO₃) and nitrite (NaNO₂) have been used for millennia to preserve food, especially meat and fish.¹⁴⁵ Food preparation leads to reduction of nitrate to nitrite, and nitrite inhibits bacterial growth, especially *Clostridium*

Table 9. Ongoing or planned trials of NO sources for prophylaxis or treatment of COVID-19 (also see²⁵⁵).

Trial name (registration)	NO source	Location	Design	Phase in population	Outcome	Sites N	Rx days	Finish
C19 prevention								
BEET-Winter (ISRCTN51124684)	Nitrate juice, oral	UK	Cluster DBPC	Phase II in care homes	New infection (any, including C-19)	30	60	06/21
Berra <i>et al.</i> (NCT04312243)	NO gas, inhaled	USA	CCS	Phase II in healthcare staff	New C-19 diagnosis	1 470	14	03/21
(NCT04408183)	GLS-1200 nasal spray (NO stimulant)	USA	DBPC	Phase II	Adverse events PCR-positive infection	2 225	28	03/21
C19 treatment								
Fiorentino <i>et al.</i> (NCT04637906)	L-arginine, oral	Italy	RCT DBPC	Phase II in hospital: on oxygen	Normalisation of P/F fraction	1 290	60	09/21
(NCT04570384)	L-citrulline, iv	USA	DBPC	Phase II in hospital: on oxygen	[L-arginine]	1 60	10	12/21
CACOLAC (NCT04404426)	L-citrulline, iv	France	DBPC	Phase II in ICU and ventilated for ARDS	SOFA score	1 32	7	09/21
COVINOX (NCT04421508)	NO gas, inhaled	USA	DBPC	Phase III in hospital: on oxygen	Death or respiratory failure	? 500	?	06/21
NOCOVID (NCT04305457)	NO gas, inhaled	China Italy USA	RCT sham	Phase II in hospital: Moderate C-19	Mechanical ventilation	3 70	28	03/21
NoCovid (NCT04290858)	NO gas, inhaled	China	RCT, open	Phase II in hospital: Moderate C-19	Need for intubation-ventilation	1 400	14	02/22
NOSARSCOVID (NCT04290871)	NO gas, inhaled	China Italy USA	RCT sham	Phase II in hospital: severe C-19, PaO ₂ /FIO ₂ <300 on air	PaO ₂ /FIO ₂ > 300 on air	4 200	14	03/21
Somberg <i>et al.</i> (NCT04601077)	NO lozenge, oral	USA	RCT DBPC	Phase II in early COVID-19 in African-Americans	Hypotension, hospitalisation	1 100	30	07/21
COVID-IND-02 (NCT04443868)	NO nasal spray/irrigation	USA	RCT DBPC	Phase II in mild COVID-19	Duration of infectivity	? 50	14	07/21
NOCOVID (NCT04337918)	NO nasal spray/irrigation	Canada	RCT open	Phase II in workers at high risk of exposure	New C-19 diagnosis	5 143	14	09/20
(NCT04460183)	Nebulised sodium nitrite and citric acid (RESP301)	UK	RCT, open	Phase II/III hospitalised COVID-19	Progression in WHO scale by ≥ 1 point	4 300	14	04/21
Sildenafil (NCT04304313)	Sildenafil, oral	China	Open	Phase II in hospital: pneumonia	Disease remission	1 10	14	11/20

ARDS: adult respiratory distress syndrome; C-19: COVID-19; CCS: case-controlled study; DBPC: double-blind placebo-controlled; iv: intravenous; RCT: randomised controlled trial; SOFA: sequential organ failure assessment; TBC: to be confirmed.

botulinum, a key and severe cause of neurotoxin poisoning. Additionally, nitrite adds colour to food,^{58,146} flavour (in part by overcoming rancid tastes) and is an antioxidant.

NO donors have also been investigated for eradicating or dispersing biofilm organisms. For example, GTN synergises with citrate and ethanol in eradicating biofilms (related to *S. aureus*, MRSE, *P. aeruginosa* and *C. albicans*) in an experimental catheter lock model.¹⁴⁷ Similarly, isosorbide mononitrate synergised with antibiotics to disperse then kill *S. aureus*.¹⁴⁸ An NO-releasing contact lens has been developed to treat microbial keratitis due to *P. aeruginosa* and *S. aureus*.¹⁴⁹

GTN may have improved outcome after infection in participants enrolled into the RIGHT-2 trial, a study where paramedics recruited patients with suspected stroke and randomised them to GTN versus sham. Overall, the trial was neutral.¹⁵⁰ However, in a planned subgroup analysis of those participants with a final diagnosis of a non-stroke mimic, functional outcome was better with GTN.¹⁵⁰ In a *post hoc* analysis of participants in this subgroup, GTN was associated with a better outcome in those with a final diagnosis of infections of the respiratory and urinary tracts which raises the possibility that NO was treating the infectious cause underlying the stroke mimic diagnosis.

The prostaglandin-cyclic adenosine-phosphodiesterase-3 system

As with the NO system, the prostaglandin-cyclic adenosine monophosphate-phosphodiesterase-3 (PG-cAMP-PDE3) system has similar vasculo-protective roles with anti-leucocyte, antiplatelet and anti-smooth muscle, and pro-endothelial effects. It is therefore interesting to note that prostaglandins (PGA₁, PGJ₂), including prostacyclin (PGI₂ and analogues), have been reported to have antiviral effects.^{151–154} Whether drugs based on these¹⁵⁵ or the PDE3 inhibitor, cilostazol, have efficacy against SARS-CoV-2 remains to be investigated. Further, endogenous NO and PGI₂ work together in the vascular tree, and it is conceivable that their potential antimicrobial effects will similarly synergise. Their combination, in the forms of ISMN and cilostazol, have been tested after stroke¹⁵⁶ but not yet reported for the prevention or treatment of infection.

Interaction between nitric oxide and vaccine efficacy

The interaction between diet, nutrition state and vaccine effectiveness has been assessed in multiple studies, principally in low–middle income countries where vaccination is paramount, especially in children, and yet where malnutrition may be widespread. In a systematic review and meta-analysis of observational studies and randomised controlled trials, there was little suggestion that malnutrition had any effect on vaccine responses¹⁵⁷; similarly, supplementation with vitamins and D, and iron and zinc, did not appear to modify responses. In preclinical studies, protein-energy malnutrition had limited influence on vaccine efficacy in mice.¹⁵⁸ The effect of dietary nitrate levels on vaccine efficacy is unstudied.

If nitric oxide derivatives attenuate microbial infections, then the efficacy of vaccines based on live attenuated viruses and bacteria (such as measles, poliovirus, BCG) might be attenuated by treatment with NO. Although there are many factors known to alter vaccine effectiveness (*e.g.* age), the effect of NO has not been studied.

Post-infection morbidity

Many infections cause long-term morbidity with chronic fatigue syndrome (CFS) and symptoms including fatigue, tiredness, myalgia, cognitive impairment and depression. Example associated microbes include *Borrelia burgdorferi* (Lyme disease), *Chlamydia pneumoniae* (community acquired pneumonia), Epstein–Barr virus (infectious mononucleosis), human herpes virus 6 (exanthema subitem), human immunodeficiency virus (AIDS), polio virus, SARS-CoV-1 virus (SARS), SARS-CoV-2 (long-COVID) and West Nile virus (fever).^{159–161} Although CFS may represent chronic or latent infection, it is more likely to reflect the presence of post-infectious chronic inflammation. Hypothetically, these patients might benefit from inorganic nitrates in view of their positive effects on exercise performance (elite athletes take beetroot juice for this purpose) and cognition,^{73,92} and potentially antimicrobial effects, a question that needs addressing (Table 7). A phase II trial of L-citrulline is studying this approach in patients with post-polio syndrome.¹⁶²

Excess nitric oxide during infection

During severe infection, sepsis (defined as “life-threatening organ dysfunction caused by a dysregulated host response to infection”) often develops. Septic shock is a subset of sepsis and is a leading cause of death worldwide.¹⁶³ It manifests as hyper- or hypo-pyrexia, altered mental state, hypotension, tachycardia, tachypnoea, hypoxia, anuria and/or lactataemia. This can occur with many infections due to:

- Gram negative bacteria: *Bacteroides fragilis*, *C. pneumoniae*, *Enterobacter* spp., *E. coli*, *Haemophilus influenzae*, *Klebsiella* spp., *Legionella* spp., *Neisseria meningitidis*, *Proteus* spp., *P. aeruginosa*, *Yersinia pestis*.⁶¹

- Gram positive bacteria: *Clostridium* spp., *Enterococcus* spp., *Listeria monocytogenes*, *Staphylococcus* spp., *Streptococcus agalactiae/pneumoniae/pyogenes*
- Viral: Adenovirus, Coronaviruses, Dengue viruses, Ebola virus, Enteroviruses, human immunodeficiency virus, Influenza virus (A and B), haemorrhagic fever viruses, Parechoviruses.^{164,165}
- Fungi: *Candida* spp.¹⁶⁶
- Protozoa: *Plasmodium falciparum*, *Schistosoma mansoni*.¹⁶⁷

Typically, autoamplification of circulating cytokines (so-called cytokine storm) leads to excess NO synthesis, mostly derived from inducible NOS, leading to high circulating NO levels and the development of septic shock. In these circumstances, treatment with exogenous NO might be inappropriate. Trials of inhibiting endogenous NO synthesis with NOS-inhibitors in critically ill patients with sepsis have been reported although, disappointingly, did not improve outcome; indeed, the non-specific NOS-inhibitor, NG-methyl-L-arginine hydrochloride (L-NMMA, 546C88), was associated with increased death.¹⁶⁸ It is not clear why inhibiting NO synthesis was ineffective but non-selective NOS inhibitors were used meaning that both toxic (iNOS) and beneficial (eNOS) sources of NO were inhibited; pharmacologically, such inhibitors will have reduced cardiac output, organ perfusion and tissue oxygenation. In the absence of licensed selective iNOS inhibitors, perhaps the analogous approach used in the management of hyperthyroidism using block (with carbimazole) and replace (thyroxine) might be effective, *i.e.* block NOS activity and replace with a low dose of a NO donor. That excess NO is dangerous does not mean that pharmacological doses of NO cannot be effective (Figure 1, Tables 6, 11) since all effective interventions in medicine have an inverted “U” dose response.

Some infections have opposing *in vitro* and *in vivo* responses to NO. For example activated macrophage-derived NO or NO donors such as SNAP reduced *Trypanosoma brucei* proliferation *in vitro*^{169,170} whereas endogenous iNOS-derived NO suppressed protozoa-antigen specific T-cell proliferative responses and so worsened infection, at least in infected mice.¹⁷⁰ Intracellular protozoal infections are unlikely to be affected in this manner since macrophage-derived NO would be able to act directly on pathogens such as *Leishmania major*.¹⁷¹

Figure 1. Schematic of concentration response curve for antimicrobial effects of nitric oxide.

1. Reduced eNOS-derived NO related to dietary insufficiency, older age, vascular disease
2. Normal eNOS-derived vascular NO
3. iNOS-derived NO or low/moderate dose exogenous NO source
4. iNOS-derived NO in septic shock or high dose exogenous NO source

Table 10. Future research questions relating to nitric oxide therapy for microbes.

Question	Microbe	<i>In vitro</i>	<i>In vivo</i>	Clinical trials
What effect does NO have on so-far unstudied pandemic microbes?	Viruses: smallpox, yellow fever, Zika. Bacteria: <i>Vibrio cholerae</i>	+		
What effect does NO have on so-far unstudied other microbes?	Bacteria: Mycoplasma. Archaea.	+	+	
What effect does NO have on micro/macro-thrombosis?	Viruses: Ebola. Influenza. MERS. SARS-CoV-1/2		+	+
What is the effect of timing on outcome in prevention or treatment of mild and severe disease?	Any			
Could NO be used as a non-specific adjuvant to antimicrobial therapy (where septic shock is absent)?	Any		+	+
Is the strategy of block (NOS inhibitor) and replace (NO donor) effective in septic shock?	Intensive Care Unit infections		+	+
Do NO sources, e.g. dietary nitrate or NO donors, prevent/treat/improve outcome after COVID-19?	SARS-CoV-2			+
Do NO sources, e.g. dietary nitrate or NO donors, prevent and treat outcome after endemic 'flu?	SARS-CoV-2			+
Do combined NO and PG sources have agonistic antimicrobial effects?	Any	+	+	+
Do NO sources reduce the efficacy of live attenuated vaccines?	Measles virus, poliovirus, bacilli Calmette-Guerin		+	+
Do NO sources reduce chronic symptoms and improve quality of life after infection?	Lyme disease			+

NO: nitric oxide; PG: prostaglandin.

Table 11. Balance between potential beneficial and hazardous effects of NO sources in preventing and treating infections.

	Benefit	Ineffective/Hazard
<i>In vitro</i>	Considerable static/cidal data	Limited neutral/negative data suggesting that there may be publication bias
<i>In vivo</i>	Some static/cidal data	
Clinical	Some positive phase II trials	
Concentration	Moderate	Low or very high (as in septic shock although NOS inhibitors ineffective)
		Microbial resistance to NO, e.g. synthesis of NO to resist oxidative stress
		Organic nitrates generate reactive NO species

Other infections do not appear, at least *in vitro*, to induce iNOS. For example, *Cryptococcus neoformans* failed to induce NOS in primed macrophages,¹⁷² apparently due to a lack of TNF- α secretion, probably because the polysaccharide capsule masked the signal for TNF- α secretion. Interestingly, non-encapsulated mutants of *C. neoformans* did induce endogenous NOS.

High levels of iNOS activation were antimicrobial in studies of malaria. Based on monocyte-derived mRNA levels in circulating blood, uncomplicated malaria was associated with increased levels of iNOS activation in contrast to patients with severe malaria who had lower levels.¹⁷³

Epidemics and pandemics

Over recorded history, most epidemics and pandemics have resulted from viral infections including Ebola (viral haemorrhagic fever), influenza (H1N1, H2N2, H3N2, H3N8), HIV-1 (AIDS), polio (poliomyelitis), smallpox, yellow fever, zika or corona (OC43, MERS-CoV, SARS-CoV-1/2) viruses. Bacterial pandemics have resulted from *Vibrio cholerae* (cholera), *S. enterica* (typhoid fever) and *Yersinia pestis* (plague). Studies *in vitro* have reported findings suggesting that NO can reduce infection for some of these pathogens (Tables 2, 3) but information appears to be lacking for smallpox, yellow fever, zika and cholera (Table 10).

With multiple pandemics over the last 100 years, it is only inevitable that further ones will occur and some, like COVID-19, will comprise a “global catastrophic biological risk”.¹⁷⁴ Global pandemics will most likely be caused by a respiratory-spread virus that crosses over from animals such that humans have no inherent immunity to it. Likely candidates include orthomyxoviruses (especially influenza A viruses such as H7N9), paramyxoviruses (*e.g.* measles, mumps, croup), pneumovirus (*e.g.* human metapneumovirus), coronaviruses and picornaviruses (especially rhinoviruses and enteroviruses). All of these have had strains that have crossed from animals to humans. This emphasis on RNA viruses is because DNA viruses tend to have lower mutation rates and, therefore, evolve more slowly and are less likely to escape the human immune system within the first rounds of infection. Nevertheless, DNA viruses, such as pox or herpes viruses from great apes or monkeys, do have the potential to jump species. Non-viral causes of pandemics are less likely since most bacteria will be treatable with broad-spectrum antibacterial agents, most fungi are thermally restricted, and prions would require massive food contamination (and only spread slowly).¹⁷⁴ Protozoa are usually thermally restricted although global warming may allow malaria to spread more widely in temperate zones.

Unfortunately, pandemics/epidemics may co-exist as seen with SARS-CoV-2 and dengue in Brazil,¹⁷⁵ and both with *S. enterica* in Pakistan;^{176,177} in part, this reflects increasing travel with aircraft providing a portal for numerous microbes.¹⁷⁸ Of theoretical concern was the potential for COVID-19 and epidemic influenza to co-exist during winter in the Northern hemisphere, this possibly leading to a dramatic increase in deaths.¹⁷⁹ Nevertheless, ‘flu rates were very low in both southern and northern hemisphere 2020 winters, presumably due to hands, face, space, mask and fresh air measures. All-in-all, the absence of a true broad-spectrum of antiviral agents is a major concern¹⁸⁰ and a potential agent such as NO with antimicrobial effects that extend beyond viruses would be most welcome.

Implications for SARS-CoV-2 and COVID-19

One possible explanation for the observation that COVID-19 outcomes are worse in older people, males, black or Asian ethnicity, and those with co-morbidities such as diabetes, hypertension, stroke and chronic lung disease,¹⁸¹ is that these groups have lower vascular NO activity^{4,5,9} and so mount a sub-optimal host response against infection. Increasing NO availability is therefore a potential therapeutic strategy. Several NO sources have potential relevance to preventing and treating COVID-19. L-arginine, sodium nitrite, GTN, SNP, NO and dipyridamole each have clinical antimicrobial activity and can be administered, variously, orally, intravenously or as NO gas in the intensive care unit. Transdermal GTN, and oral ISMN, dipyridamole and sildenafil may be administered in the community or hospital. Of these, NO gas, dipyridamole and sildenafil are already being tested for preventing or treating COVID-19 (Table 9). It remains to be determined if increasing dietary nitrate may be a cost effective and safe intervention of widespread health relevance for the prevention of COVID-19 and, indeed, other emerging, pandemic, epidemic or endemic infections. Recent trial evidence provides indirect supporting evidence for the potential anti-SARS-CoV-2 effect of NO. First, dexamethasone and tocilizumab reduced death in patients in intensive care units,^{182,183} and these agents and NO share anti-inflammatory effects. And second, interferon- β reduced the need for intensive care in COVID-19 patients;¹⁸⁴ type I interferons increase iNOS activity and so have antimicrobial effects, as seen with *L. major* and *Burkholderia pseudomallei*.^{185,186}

Discussion and conclusions

Nitric oxide is a fundamental molecule with wide-ranging and potent vascular, anti-platelet, anti-inflammatory and tumoricidal effects. Further, there is a large volume of literature spanning the last 30+ years demonstrating that NO also has potent *in vitro* antimicrobial effects on a wide variety of viruses, bacteria, protozoa, fungi and yeasts; these are supported by a modest number of *in vivo* studies. Further, several positive clinical phase II trials of NO have been reported in viral, bacterial, protozoa and fungal infections, these relating particularly to skin and respiratory infections administered by cream and gas respectively. Although not from randomised trials, there is also evidence that dietary nitrate modifies the oral biome and so reduces dental caries.

However, these results cannot be considered persuasive on their own. First, few neutral or negative studies have been reported suggesting that there may be a risk of publication bias. Second, conflicting data in some dual-protocol studies with positive *in vitro* and neutral/negative *in vivo* data suggest that although NO is antimicrobial *per se*, the local tissue environment may overcome or reverse this effect. Third, organic nitrates can suffer from tolerance and may lead to the generation of reactive NO species such as peroxynitrite and S-nitrosothiols which might exacerbate rather than attenuate

infection. Fourth, resistance may develop although this seems unlikely to be a generic issue, not least because NO levels can change, and be changed, much faster than any microbe can raise defensive mechanisms. Fifth, some microbes can produce their own NO and use this to resist the oxidative stress induced by external NO and its derivatives. Sixth, excess NO production is associated with the development of septic shock which might suggest that any NO is ineffective. Potentially, unsuccessful trials of non-selective NOS-inhibitors in severe sepsis may have confused the issue, perhaps by suggesting that treatment with NO is not important in infection. Seventh, positive clinical studies have been performed in environments where very high local concentrations of NO can be achieved and without the risk of reactive responses, in particular on the surface of tissues such as cream on the skin, dietary nitrate in the mouth, nitrite in the stomach, NO gas in the lungs and nitrite in the bladder; whether NO is effective as an antimicrobial within tissues and the vascular tree remains to be determined.

There are many sources of NO suitable for studying the prevention and treatment of milder infections in the community and hospital (*e.g.* topical sodium nitrite, oral NO donors such as ISMN, or oral PDE5 inhibitors such as dipyridamole or sildenafil), and treatment of serious infections in hospital (*e.g.* intravenous L-arginine, sodium nitrite or NO donors such as GTN or SNP, of NO gas). NO may also be delivered *via* a high nitrate diet, thus offering a widely available and inexpensive public health approach to potentially reducing and attenuating the severity of infections worldwide. This approach has the added advantage that such diets are already known to reduce vascular disease and some cancers, and possibly other inflammatory diseases and dementia.

In summary, the wealth of *in vitro* data suggest that NO has generic antimicrobial effects. However, some data suggest that NO may be ineffective or even hazardous and these reinforce our view for the need for large scale clinical trials of NO donors in the community and hospitals to prevent and treat infections. Although such studies need to focus urgently on the COVID-19 pandemic (especially with the lack of broad spectrum antiviral agents¹⁸⁰), other pathogens also need to be targeted. However, patients with established septic shock should not be administered NO donors to avoid exacerbating vascular collapse. One utopian vision would be demonstration that high dietary nitrate intake produces pre- or post-exposure prophylaxis against infections and their severity in the community whilst NO donors are effective antimicrobial treatments for use by general practitioners and in hospitals.

Data availability

No data are associated with this article.

References

- Palmer RMJ, Ashton DS, Moncada S: **Vascular endothelial cells synthesise nitric oxide from L-arginine.** *Nature.* 1988; **333**(6174): 664–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bath PMW, Hassall DG, Gladwin A-M, *et al.*: **Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro.** *Arterioscler Thromb.* 1991; **11**: 254–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Radomski MW, Palmer RMJ, Moncada S: **Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium.** *Lancet.* 1987; **ii**: 1057–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ferlito S, Gallina M, Pitari GM, *et al.*: **Nitric oxide plasma levels in patients with chronic and acute cerebrovascular disorders.** *Panminerva Med.* 1998; **40**: 51–4.
[PubMed Abstract](#)
- Rashid P, Bath P: **Plasma nitric oxide (nitrate) in stroke by type, severity and outcome.** *Stroke.* 2000; **31**: 2835 (abstract).
[PubMed Abstract](#) | [Publisher Full Text](#)
- Keller TT, Mairuhu AT, de Kruif MD, *et al.*: **Infections and endothelial cells.** *Cardiovasc Res.* 2003; **60**(1): 40–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Varga Z, Flammer AJ, Steiger P, *et al.*: **Endothelial cell infection and endotheliitis in COVID-19.** *Lancet.* 2020; **395**(10234): 1417–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ahmed S, Zimba O, Gasparyan AY: **Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad.** *Clin Rheumatol.* 2020.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Green SJ: **Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency.** *Microbes Infect.* 2020; **22**(4-5): 149–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Griffith TM, Edwards DH, Lewis MJ, *et al.*: **Evidence that cyclic guanosine monophosphate (Cgmp) mediates endothelium-dependent relaxation.** *Eur J Pharmacol.* 1985; **112**(2): 195–202.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Radomski MW, Palmer RM, Moncada S: **The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium.** *Biochem Biophys Res Commun.* 1987; **148**(3): 1482–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lowenstein CJ, Dinerman JL, Snyder SH: **Nitric oxide: a physiologic messenger.** *Ann Intern Med.* 1994; **120**(3): 227–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
- De Groote MA, Fang FC: **NO inhibitions: antimicrobial properties of nitric oxide.** *Clin Infect Dis.* 1995; **21**(Suppl 2): S162–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fang FC: **Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity.** *J Clin Invest.* 1997; **99**(12): 2818–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Vallance P, Charles I: **Nitric oxide as an antimicrobial agent: does NO always mean NO?** *Gut.* 1998; **42**(3): 313–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Reiss CS, Komatsu T: **Does nitric oxide play a critical role in viral infections?** *J Virol.* 1998; **72**(6): 4547–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Burgner D, Rockett K, Kwiatkowski D: **Nitric oxide and infectious diseases.** *Arch Dis Child.* 1999; **81**(2): 185–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Akaike T, Maeda H: **Nitric oxide and virus infection.** *Immunology.* 2000; **101**(3): 300–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Xu W, Zheng S, Dweik RA, *et al.*: **Role of epithelial nitric oxide in airway viral infection.** *Free Radic Biol Med.* 2006; **41**(1): 19–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

20. Schairer DO, Chouake JS, Nosanchuk JD, *et al.*: **The potential of nitric oxide releasing therapies as antimicrobial agents.** *Virulence*. 2012; **3**(3): 271–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Stamler JS, Singel DJ, Loscalzo J: **Biochemistry of nitric oxide and its redox-activated forms.** *Science*. 1992; **258**(5090): 1898–902.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Koshland DJ: **The molecule of the year.** *Science*. 1992; **258**(5090): 1861.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Howlett R: **Nobel award stirs up debate on nitric oxide breakthrough.** *Nature*. 1998; **395**(6703): 625–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Sohlman R: *The Legacy of Alfred Nobel, The Story Behind The Nobel Prizes*. London: The Bodley Head; 1983.
25. Baltimore D: **Expression of animal virus genomes.** *Bacteriol Rev*. 1971; **35**(3): 235–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Lane TE, Paoletti AD, Buchmeier MJ: **Disassociation between the in vitro and in vivo effects of nitric oxide on a neurotropic murine coronavirus.** *J Virol*. 1997; **71**(3): 2202–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Jung K, Gurnani A, Renukaradhya GJ, *et al.*: **Nitric oxide is elicited and inhibits viral replication in pigs infected with porcine respiratory coronavirus but not porcine reproductive and respiratory syndrome virus.** *Vet Immunol Immunopathol*. 2010; **136**(3–4): 335–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Keyaerts E, Vijgen L, Chen L, *et al.*: **Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound.** *Int J Infect Dis*. 2004; **8**(4): 223–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Akerström S, Mousavi-Jazi M, Klingström J, *et al.*: **Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus.** *J Virol*. 2005; **79**(3): 1966–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Goldshtein M, Lerner O, Kalaora R, *et al.*: **Nitric oxide is a powerful anti-coronavirus-inhaled agent that acts within hours.** *Chest*. 2020; **158**(4): 2446A–7A.
[Publisher Full Text](#) | [Free Full Text](#)
31. Chen L, Liu P, Gao H, *et al.*: **Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing.** *Clin Infect Dis*. 2004; **39**(10): 1531–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Akaberi D, Krambrich J, Ling J, *et al.*: **Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro.** *Redox Biol*. 2020; **37**: 101734.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Liu X, Li Z, Liu S, *et al.*: **Potential therapeutic effects of dipyrindamole in the severely ill patients with COVID-19.** *Acta Pharm Sin B*. 2020.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Lisi F, Zelikin AN, Chandrawati R: **Nitric Oxide to Fight Viral Infections.** *Adv Sci (Weinh)*. 2021; **8**(7): 2003895.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Jiang Y, Fang L, Luo R, *et al.*: **N-acetylpenicillamine inhibits the replication of porcine reproductive and respiratory syndrome virus in vitro.** *Vet Res Commun*. 2010; **34**(7): 607–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Kaul P, Singh I, Turner RB: **Effect of nitric oxide on rhinovirus replication and virus-induced interleukin-8 elaboration.** *Am J Respir Crit Care Med*. 1999; **159**(4 Pt 1): 1193–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Kono Y, Shibata H, Adachi K, *et al.*: **Lactate-dependent killing of Escherichia coli by nitrite plus hydrogen peroxide: a possible role of nitrogen dioxide.** *Arch Biochem Biophys*. 1994; **311**(1): 153–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. De Groote MA, Granger D, Xu Y, *et al.*: **Genetic and redox determinants of nitric oxide cytotoxicity in a Salmonella typhimurium model.** *Proc Natl Acad Sci U S A*. 1995; **92**(14): 6399–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Wink DA, Kasprzak KS, Maragos CM, *et al.*: **DNA deaminating ability and genotoxicity of nitric oxide and its progenitors.** *Science*. 1991; **254**(5034): 1001–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Fujikura Y, Kudlackova P, Vokurka M, *et al.*: **The effect of nitric oxide on vaccinia virus-encoded ribonucleotide reductase.** *Nitric Oxide*. 2009; **20**(2): 114–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Granger DL, Lehninger AL: **Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells.** *J Cell Biol*. 1982; **95**(2 Pt 1): 527–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Saura M, Zaragoza C, McMillan A, *et al.*: **An antiviral mechanism of nitric oxide: inhibition of a viral protease.** *Immunity*. 1999; **10**(1): 21–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Mokry RL, Schumacher ML, Hogg N, *et al.*: **Nitric Oxide Circumvents Virus-Mediated Metabolic Regulation during Human Cytomegalovirus Infection.** *mBio*. 2020; **11**(6).
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. O'Leary V, Solberg M: **Effect of sodium nitrite inhibition on intracellular thiol groups and on the activity of certain glycolytic enzymes in Clostridium perfringens.** *Appl Environ Microbiol*. 1976; **31**(2): 208–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Frawley ER, Karlinsey JE, Singhal A, *et al.*: **Nitric Oxide Disrupts Zinc Homeostasis in Salmonella enterica Serovar Typhimurium.** *mBio*. 2018; **9**(4).
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Carpenter AW, Schoenfish MH: **Nitric oxide release: part II. Therapeutic applications.** *Chem Soc Rev*. 2012; **41**(10): 3742–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Mehta DR, Ashkar AA, Mossman KL: **The nitric oxide pathway provides innate antiviral protection in conjunction with the type I interferon pathway in fibroblasts.** *PLoS One*. 2012; **7**(2): e31688.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Schön T, Elias D, Moges F, *et al.*: **Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis.** *Eur Respir J*. 2003; **21**(3): 483–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Henry BM, de Oliveira MHS, Benoit S, *et al.*: **Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.** *Clin Chem Lab Med*. 2020; **58**(7): 1021–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Bikdeli B, Madhavan MV, Jimenez D, *et al.*: **COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.** *J Am Coll Cardiol*. 2020; **75**(23): 2950–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Zamanian RT, Pollack CV, Gentile MA, *et al.*: **Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection.** *Am J Respir Crit Care Med*. 2020; **202**(1): 130–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Zumft WG: **The biological role of nitric oxide in bacteria.** *Arch Microbiol*. 1993; **160**(4): 253–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Chen Y, Rosazza JP: **Purification and characterization of nitric oxide synthase (NOSNoc) from a Nocardia species.** *J Bacteriol*. 1995; **177**(17): 5122–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Sudhamsu J, Crane BR: **Bacterial nitric oxide synthases: what are they good for?** *Trends Microbiol*. 2009; **17**(5): 212–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Gusarov I, Shatalin K, Starodubtseva M, *et al.*: **Endogenous nitric oxide protects bacteria against a wide spectrum of antibiotics.** *Science*. 2009; **325**(5946): 1380–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Li DD, Yang CC, Liu P, *et al.*: **Effect of Nitric Oxide on the Antifungal Activity of Oxidative Stress and Azoles Against Candida albicans.** *Indian J Microbiol*. 2016; **56**(2): 214–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Chaudhari SS, Kim M, Lei S, *et al.*: **Nitrite Derived from Endogenous Bacterial Nitric Oxide Synthase Activity Promotes Aerobic Respiration.** *mBio*. 2017; **8**(4).
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Ras G, Leroy S, Talon R: **Nitric oxide synthase: What is its potential role in the physiology of staphylococci in meat products?** *Int J Food Microbiol*. 2018; **282**: 28–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Hendriks J, Oubrie A, Castresana J, *et al.*: **Nitric oxide reductases in bacteria.** *Biochim Biophys Acta*. 2000; **1459**(2–3): 266–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Poole RK: **Flavohaemoglobin: the pre-eminent nitric oxide-detoxifying machine of microorganisms.** *F1000Res*. 2020; **9**.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Sebbane F, Lemaitre N, Sturdevant DE, *et al.*: **Adaptive response of Yersinia pestis to extracellular effectors of innate immunity during bubonic plague.** *Proc Natl Acad Sci U S A*. 2006; **103**(31):

- 11766–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Stern AM, Hay AJ, Liu Z, *et al.*: **The NorR regulon is critical for *Vibrio cholerae* resistance to nitric oxide and sustained colonization of the intestines.** *mBio*. 2012; **3**(2): e00013–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 63. Visca P, Fabozzi G, Milani M, *et al.*: **Nitric oxide and *Mycobacterium leprae* pathogenicity.** *IUBMB Life*. 2002; **54**(3): 95–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. Workman AD, Carey RM, Kohanski MA, *et al.*: **Relative susceptibility of airway organisms to antimicrobial effects of nitric oxide.** *Int Forum Allergy Rhinol*. 2017; **7**(8): 770–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. Privett BJ, Broadnax AD, Bauman SJ, *et al.*: **Examination of bacterial resistance to exogenous nitric oxide.** *Nitric Oxide*. 2012; **26**(3): 169–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 66. Baudouin SV, Bath P, Martin JF, *et al.*: **L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance.** *Br J Clin Pharmacol*. 1993; **36**(1): 45–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 67. Ishikawa K, Kanamasa K, Ogawa I, *et al.*: **Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group.** *Jpn Circ J*. 1996; **60**(10): 779–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Redfield MM, Anstrom KJ, Levine JA, *et al.*: **Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.** *N Engl J Med*. 2015; **373**(24): 2314–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 69. Omar SA, Artime E, Webb AJ: **A comparison of organic and inorganic nitrates/nitrites.** *Nitric Oxide*. 2012; **26**(4): 229–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Daiber A, Münzel T: **Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress.** *Antioxid Redox Signal*. 2015; **23**(11): 899–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 71. Chen Z, Zhang J, Stamler JS: **Identification of the enzymatic mechanism of nitroglycerin bioactivation.** *Proc Natl Acad Sci U S A*. 2002; **99**(12): 8306–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 72. Bath P: **The effect of nitric oxide-donating vasodilators on monocyte chemotaxis and intracellular cGMP concentration in vitro.** *Eur J Clin Pharmacol*. 1993; **45**(1): 53–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. Mills CE, Khatri J, Maskell P, *et al.*: **It is rocket science - why dietary nitrate is hard to 'beet'! Part II: further mechanisms and therapeutic potential of the nitrate-nitrite-NO pathway.** *Br J Clin Pharmacol*. 2017; **83**(1): 140–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 74. Duncan C, Dougall H, Johnston P, *et al.*: **Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate.** *Nat Med*. 1995; **1**(6): 546–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
 75. Lundberg JO, Gladwin MT, Ahluwalia A, *et al.*: **Nitrate and nitrite in biology, nutrition and therapeutics.** *Nat Chem Biol*. 2009; **5**(12): 865–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 76. Doel JJ, Benjamin N, Hector MP, *et al.*: **Evaluation of bacterial nitrate reduction in the human oral cavity.** *Eur J Oral Sci*. 2005; **113**(1): 14–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 77. Khatri J, Mills CE, Maskell P, *et al.*: **It is rocket science - why dietary nitrate is hard to 'beet'! Part I: twists and turns in the realization of the nitrate-nitrite-NO pathway.** *Br J Clin Pharmacol*. 2017; **83**(1): 129–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 78. Koch CD, Gladwin MT, Freeman BA, *et al.*: **Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.** *Free Radic Biol Med*. 2017; **105**: 48–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 79. Shimazu T, Kuriyama S, Hozawa A, *et al.*: **Dietary patterns and cardiovascular disease mortality in Japan: a prospective cohort study.** *Int J Epidemiol*. 2007; **36**(3): 600–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 80. Fung TT, Chiuve SE, McCullough ML, *et al.*: **Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women.** *Arch Intern Med*. 2008; **168**(7): 713–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 81. Widmer RJ, Flammer AJ, Lerman LO, *et al.*: **The Mediterranean diet, its components, and cardiovascular disease.** *Am J Med*. 2015; **128**(3): 229–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 82. Estruch R, Ros E, Salas-Salvadó J, *et al.*: **Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts.** *N Engl J Med*. 2018; **378**(25): e34.
[PubMed Abstract](#) | [Publisher Full Text](#)
 83. Bryan NS, Alexander DD, Coughlin JR, *et al.*: **Ingested nitrate and nitrite and stomach cancer risk: an updated review.** *Food Chem Toxicol*. 2012; **50**(10): 3646–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
 84. Butler A: **Nitrites and nitrates in the human diet: Carcinogens or beneficial hypotensive agents?** *J Ethnopharmacol*. 2015; **167**: 105–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 85. Zhang FX, Miao Y, Ruan JG, *et al.*: **Association Between Nitrite and Nitrate Intake and Risk of Gastric Cancer: A Systematic Review and Meta-Analysis.** *Med Sci Monit*. 2019; **25**: 1788–99.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 86. Webb AJ, Patel N, Loukogeorgakis S, *et al.*: **Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite.** *Hypertension*. 2008; **51**(3): 784–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 87. Kapil V, Millsom AB, Okorie M, *et al.*: **Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived NO.** *Hypertension*. 2010; **56**(2): 274–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
 88. Presley TD, Morgan AR, Bechtold E, *et al.*: **Acute effect of a high nitrate diet on brain perfusion in older adults.** *Nitric Oxide*. 2011; **24**(1): 34–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 89. Velmurugan S, Gan JM, Rathod KS, *et al.*: **Dietary nitrate improves vascular function in patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled study.** *Am J Clin Nutr*. 2016; **103**(1): 25–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 90. Mills CE, Govoni V, Faconti L, *et al.*: **Reducing Arterial Stiffness Independently of Blood Pressure. The VaSera Trial.** *J Am Coll Cardiol*. 2017; **70**(13): 1683–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 91. Faconti L, Mills CE, Govoni V, *et al.*: **Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomized controlled VaSera trial.** *Br J Clin Pharmacol*. 2019; **85**(1): 169–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 92. Stanaway L, Rutherford-Markwick K, Page R, *et al.*: **Performance and Health Benefits of Dietary Nitrate Supplementation in Older Adults: A Systematic Review.** *Nutrients*. 2017; **9**(11).
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 93. Omar SA, Fok H, Tilgner KD, *et al.*: **Paradoxical normoxia-dependent selective actions of inorganic nitrite in human muscular conduit arteries and related selective actions on central blood pressures.** *Circulation*. 2015; **131**(4): 381–9; discussion 9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 94. Ashor AW, Lara J, Siervo M: **Medium-term effects of dietary nitrate supplementation on systolic and diastolic blood pressure in adults: a systematic review and meta-analysis.** *J Hypertens*. 2017; **35**(7): 1353–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 95. Kapil V, Khambata RS, Robertson A, *et al.*: **Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study.** *Hypertension*. 2015; **65**(2): 320–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 96. Raubenheimer K, Bondonno C, Blekkenhorst L, *et al.*: **Effects of dietary nitrate on inflammation and immune function, and implications for cardiovascular health.** *Nutr Rev*. 2019.
[PubMed Abstract](#) | [Publisher Full Text](#)
 97. Lundberg JO, Carlström M, Weitzberg E: **Metabolic Effects of Dietary Nitrate in Health and Disease.** *Cell Metab*. 2018; **28**(1): 9–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
 98. Bushnell C, Beavers D, Miller G, *et al.*: **Dietary Nitrate Supplements and Ischemic Stroke Recovery: A Pilot Study.** *Stroke*. 2017; **48**: AWP166.

99. Ormesher L, Myers JE, Chmiel C, *et al.*: **Effects of dietary nitrate supplementation, from beetroot juice, on blood pressure in hypertensive pregnant women: A randomised, double-blind, placebo-controlled feasibility trial.** *Nitric Oxide*. 2018; **80**: 37–44. [PubMed Abstract](#) | [Publisher Full Text](#)
100. Bailey SJ, Blackwell JR, Williams E, *et al.*: **Two weeks of watermelon juice supplementation improves nitric oxide bioavailability but not endurance exercise performance in humans.** *Nitric Oxide*. 2016; **59**: 10–20. [PubMed Abstract](#) | [Publisher Full Text](#)
101. McIlvenna LC, Monaghan C, Liddle L, *et al.*: **Beetroot juice versus chard gel: A pharmacokinetic and pharmacodynamic comparison of nitrate bioavailability.** *Nitric Oxide*. 2017; **64**: 61–7. [PubMed Abstract](#) | [Publisher Full Text](#)
102. Isidori AM, Giannetta E, Pofi R, *et al.*: **Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project.** *Andrology*. 2021; **9**(1): 33–38. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
103. Mostafa T: **Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?** *Sex Med Rev*. 2021; **9**(1): 15–22. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
104. Martel J, Ko YF, Young JD, *et al.*: **Could nasal nitric oxide help to mitigate the severity of COVID-19?** *Microbes Infect*. 2020; **22**(4–5): 168–71. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
105. Adler BL, Friedman AJ: **Nitric oxide therapy for dermatologic disease.** *Future Sci OA*. 2015; **1**(1): FSO37. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
106. Lautner G, Meyerhoff ME, Schwendeman SP: **Biodegradable poly (lactic-co-glycolic acid) microspheres loaded with S-nitroso-N-acetyl-D-penicillamine for controlled nitric oxide delivery.** *J Control Release*. 2016; **225**: 133–139. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
107. Pieretti JC, Rubilar O, Weller RB, *et al.*: **Nitric oxide (NO) and nanoparticles - Potential small tools for the war against COVID-19 and other human coronavirus infections.** *Virus Res*. 2021; **291**: 198202. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
108. Contreras Lancheros CA, Pelegrino MT, Kian D, *et al.*: **Selective Antiprotozoal Activity of Nitric Oxide-releasing Chitosan Nanoparticles Against Trypanosoma cruzi: Toxicity and Mechanisms of Action.** *Curr Pharm Des*. 2018; **24**(7): 830–9. [PubMed Abstract](#) | [Publisher Full Text](#)
109. Pelegrino MT, Pieretti JC, Nakazato G, *et al.*: **Chitosan chemically modified to deliver nitric oxide with high antibacterial activity.** *Nitric Oxide*. 2021; **106**: 24–34. [PubMed Abstract](#) | [Publisher Full Text](#)
110. Sysel AM, Dunphy MJ, Bauer JA: **Antimicrobial properties of diethylamine NONOate, a nitric oxide donor, against Escherichia coli: a pilot study.** *J Antibiot (Tokyo)*. 2021; **74**(4): 260–5. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
111. Goudie MJ, Pant J, Handa H: **Liquid-infused nitric oxide-releasing (LINOREl) silicone for decreased fouling, thrombosis, and infection of medical devices.** *Sci Rep*. 2017; **7**(1): 13623. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
112. Pant J, Goudie MJ, Chaji SM, *et al.*: **Nitric oxide releasing vascular catheters for eradicating bacterial infection.** *J Biomed Mater Res B Appl Biomater*. 2018; **106**(8): 2849–57. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
113. Duncan C, Li H, Dykhuizen R, *et al.*: **Protection against oral and gastrointestinal diseases: importance of dietary nitrate intake, oral nitrate reduction and enterosalivary nitrate circulation.** *Comp Biochem Physiol A Physiol*. 1997; **118**(4): 939–48. [PubMed Abstract](#) | [Publisher Full Text](#)
114. Hohensinn B, Haselgrübler R, Müller U, *et al.*: **Sustaining elevated levels of nitrite in the oral cavity through consumption of nitrate-rich beetroot juice in young healthy adults reduces salivary pH.** *Nitric Oxide*. 2016; **60**: 10–15. [PubMed Abstract](#) | [Publisher Full Text](#)
115. Vanhatalo A, Blackwell JR, L'Heureux JE, *et al.*: **Nitrate-responsive oral microbiome modulates nitric oxide homeostasis and blood pressure in humans.** *Free Radic Biol Med*. 2018; **124**: 21–30. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
116. Burleigh MC, Liddle L, Monaghan C, *et al.*: **Salivary nitrite production is elevated in individuals with a higher abundance of oral nitrate-reducing bacteria.** *Free Radic Biol Med*. 2018; **120**: 80–8. [PubMed Abstract](#) | [Publisher Full Text](#)
117. Dougall HT, Smith L, Duncan C, *et al.*: **The effect of amoxycillin on salivary nitrite concentrations: an important mechanism of adverse reactions?** *Br J Clin Pharmacol*. 1995; **39**(4): 460–2. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
118. Dykhuizen RS, Fraser A, McKenzie H, *et al.*: **Helicobacter pylori is killed by nitrite under acidic conditions.** *Gut*. 1998; **42**(3): 334–7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
119. Halliday GM, Byrne SN: **An unexpected role: UVA-induced release of nitric oxide from skin may have unexpected health benefits.** *J Invest Dermatol*. 2014; **134**(7): 1791–4. [PubMed Abstract](#) | [Publisher Full Text](#)
120. Weller RB: **Sunlight Has Cardiovascular Benefits Independently of Vitamin D.** *Blood Purif*. 2016; **41**(1–3): 130–4. [PubMed Abstract](#) | [Publisher Full Text](#)
121. Weller R, Ormerod AD, Hobson RP, *et al.*: **A randomized trial of acidified nitrite cream in the treatment of tinea pedis.** *J Am Acad Dermatol*. 1998; **38**(4): 559–63. [PubMed Abstract](#) | [Publisher Full Text](#)
122. Ormerod AD, White MI, Shah SA, *et al.*: **Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream.** *Br J Dermatol*. 1999; **141**(6): 1051–3. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
123. Davidson RN, Yardley V, Croft SL, *et al.*: **A topical nitric oxide-generating therapy for cutaneous leishmaniasis.** *Trans R Soc Trop Med Hyg*. 2000; **94**(3): 319–22. [PubMed Abstract](#) | [Publisher Full Text](#)
124. Phillips R, Adjei O, Lucas S, *et al.*: **Pilot randomized double-blind trial of treatment of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxides.** *Antimicrob Agents Chemother*. 2004; **48**(8): 2866–70. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
125. Ormerod AD, Shah AA, Li H, *et al.*: **An observational prospective study of topical acidified nitrite for killing methicillin-resistant Staphylococcus aureus (MRSA) in contaminated wounds.** *BMC Res Notes*. 2011; **4**: 458. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
126. Ormerod AD, van Voorst Vader PC, Majewski S, *et al.*: **Evaluation of the Efficacy, Safety, and Tolerability of 3 Dose Regimens of Topical Sodium Nitrite With Citric Acid in Patients With Anogenital Warts: A Randomized Clinical Trial.** *JAMA Dermatol*. 2015; **151**(8): 854–61. [PubMed Abstract](#) | [Publisher Full Text](#)
127. Concannon M, Keogh L, Stephenson J, *et al.*: **A randomized comparative evaluation of clinical and home application to investigate the effectiveness of silver nitrate (AgNO₃).** *Int J Pharm Pract*. 2017; **25**(6): 421–8. [PubMed Abstract](#) | [Publisher Full Text](#)
128. Runer T, Cervin A, Lindberg S, *et al.*: **Nitric oxide is a regulator of mucociliary activity in the upper respiratory tract.** *Otolaryngol Head Neck Surg*. 1998; **119**(3): 278–87. [PubMed Abstract](#) | [Publisher Full Text](#)
129. Ricciardolo FL: **Multiple roles of nitric oxide in the airways.** *Thorax*. 2003; **58**(2): 175–82. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
130. Zemke AC, Shiva S, Burns JL, *et al.*: **Nitrite modulates bacterial antibiotic susceptibility and biofilm formation in association with airway epithelial cells.** *Free Radic Biol Med*. 2014; **77**: 307–16. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
131. Gómez FP, Amado VM, Roca J, *et al.*: **Effect of nitric oxide inhalation on gas exchange in acute severe pneumonia.** *Respir Physiol Neurobiol*. 2013; **187**(2): 157–63. [PubMed Abstract](#) | [Publisher Full Text](#)
132. Abou-Arab O, Huette P, Debouvries F, *et al.*: **Inhaled nitric oxide for critically ill Covid-19 patients: a prospective study.** *Crit Care*. 2020; **24**(1): 645. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
133. Lotz C, Muellenbach RM, Meybohm P, *et al.*: **Effects of inhaled nitric oxide in COVID-19-induced ARDS - Is it worthwhile?** *Acta Anaesthesiol Scand*. 2020. [PubMed Abstract](#) | [Publisher Full Text](#)
134. Longobardo A, Montanari C, Shulman R, *et al.*: **Inhaled nitric oxide minimally improves oxygenation in COVID-19 related acute respiratory distress syndrome.** *Br J Anaesth*. 2021; **126**(1): e44–e6. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
135. Safaee Fakhri B, Wiegand SB, Pinciroli R, *et al.*: **High Concentrations of Nitric Oxide Inhalation Therapy in Pregnant Patients With Severe Coronavirus Disease 2019 (COVID-19).** *Obstet Gynecol*. 2020; **136**(6): 1109–13. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
136. Garfield B, McFadyen C, Briar C, *et al.*: **Potential for personalised application of inhaled nitric oxide in COVID-19 pneumonia.** *Br J Anaesth*. 2021; **126**(2): e72–e5. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

137. Carlsson S, Govoni M, Wiklund NP, *et al.*: **In Vitro Evaluation of a New Treatment for Urinary Tract Infections Caused by Nitrate-Reducing Bacteria.** *Antimicrobial Agents and Chemotherapy*. 2003; **47**(12): 3713–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
138. Carlsson S, Weitzberg E, Wiklund P, *et al.*: **Intravesical nitric oxide delivery for prevention of catheter-associated urinary tract infections.** *Antimicrob Agents Chemother*. 2005; **49**(6): 2352–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
139. Kishikawa H, Ebberly A, Römmling U, *et al.*: **Control of pathogen growth and biofilm formation using a urinary catheter that releases antimicrobial nitrogen oxides.** *Free Radic Biol Med*. 2013; **65**: 1257–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
140. Jansson OT, Morcos E, Brundin L, *et al.*: **The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer.** *Br J Cancer*. 1998; **78**(5): 588–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
141. Morcos E, Jansson OT, Adolfsson J, *et al.*: **Bacillus Calmette-Guérin induces long-term local formation of nitric oxide in the bladder via the induction of nitric oxide synthase activity in urothelial cells.** *J Urol*. 2001; **165**(2): 678–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
142. Curtis N, Sparrow A, Ghebreyesus TA, *et al.*: **Considering BCG vaccination to reduce the impact of COVID-19.** *Lancet*. 2020; **395**(10236): 1545–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
143. Mohapatra PR, Mishra B, Behera B: **BCG vaccination induced protection from COVID-19.** *Indian J Tuberc*. 2020; In press.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
144. de Chaisemartin C, de Chaisemartin L: **BCG vaccination in infancy does not protect against COVID-19: Evidence from a natural experiment in Sweden.** *Clin Infect Dis*. 2020.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
145. Kevil CG, Kolluru GK, Pattillo CB, *et al.*: **Inorganic nitrite therapy: historical perspective and future directions.** *Free Radic Biol Med*. 2011; **51**(3): 576–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
146. Ras G, Bailly X, Chacornac JP, *et al.*: **Contribution of nitric oxide synthase from coagulase-negative staphylococci to the development of red myoglobin derivatives.** *Int J Food Microbiol*. 2018; **266**: 310–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
147. Rosenblatt J, Reitzel R, Dvorak T, *et al.*: **Glyceryl trinitrate complements citrate and ethanol in a novel antimicrobial catheter lock solution to eradicate biofilm organisms.** *Antimicrob Agents Chemother*. 2013; **57**(8): 3555–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
148. Hasan S, Albayaty YNS, Thierry B, *et al.*: **Mechanistic studies of the antibiofilm activity and synergy with antibiotics of isosorbide mononitrate.** *Eur J Pharm Sci*. 2018; **115**: 50–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
149. Aveyard J, Deller RC, Lacey R, *et al.*: **Antimicrobial Nitric Oxide Releasing Contact Lens Gels for the Treatment of Microbial Keratitis.** *ACS Appl Mater Interfaces*. 2019; **11**(41): 37491–501.
[PubMed Abstract](#) | [Publisher Full Text](#)
150. RIGHT-2 Investigators: **Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial.** *Lancet*. 2019; **393**(10175): 1009–20.
[Publisher Full Text](#)
151. D'Onofrio C, Amici C, Puglianiello A, *et al.*: **Comparative anti-viral and anti-proliferative activity of PGA1 and PGJ2 against HTLV-I-infected MT-2 cells.** *Int J Cancer*. 1992; **51**(3): 481–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
152. Zardi EM, Vespasiani Gentilucci U, Picardi A, *et al.*: **Iloprost: an adjunctive approach to chronic viral hepatitis treatment.** *Med Hypotheses*. 2005; **64**(1): 46–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
153. Whitney JB, Asmal M, Geiben-Lynn R: **Serpin induced antiviral activity of prostaglandin synthetase-2 against HIV-1 replication.** *PLoS One*. 2011; **6**(4): e18589.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
154. Rezaee F, Harford TJ, Linfield DT, *et al.*: **cAMP-dependent activation of protein kinase A attenuates respiratory syncytial virus-induced human airway epithelial barrier disruption.** *PLoS One*. 2017; **12**(7): e0181876.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
155. Das UN: **Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?** *Arch Med Res*. 2020; **51**(3): 282–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
156. Blair GW, Appleton JP, Flaherty K, *et al.*: **Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial.** *EClinicalMedicine*. 2019; **11**: 34–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
157. Savy M, Edmond K, Fine PE, *et al.*: **Landscape analysis of interactions between nutrition and vaccine responses in children.** *J Nutr*. 2009; **139**(11): 2154S–218S.
[PubMed Abstract](#) | [Publisher Full Text](#)
158. Hoang T, Agger EM, Cassidy JP, *et al.*: **Protein energy malnutrition during vaccination has limited influence on vaccine efficacy but abolishes immunity if administered during Mycobacterium tuberculosis infection.** *Infect Immun*. 2015; **83**(5): 2118–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
159. Moldofsky H, Patcai J: **Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study.** *BMC Neurol*. 2011; **11**: 37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
160. Rasa S, Nora-Krukke Z, Henning N, *et al.*: **Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).** *J Transl Med*. 2018; **16**(1): 268.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
161. Wilson C: **Concern coronavirus may trigger post-viral fatigue syndromes.** *New Sci*. 2020; **246**(3278): 10–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
162. Schmidt S, Gocheva V, Zumbunn T, *et al.*: **Treatment with L-citrulline in patients with post-polio syndrome: study protocol for a single-center, randomised, placebo-controlled, double-blind trial.** *Trials*. 2017; **18**(1): 116.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
163. Chousterman BG, Swirski FK, Weber GF: **Cytokine storm and sepsis disease pathogenesis.** *Semin Immunopathol*. 2017; **39**(5): 517–28.
[PubMed Abstract](#) | [Publisher Full Text](#)
164. Torre D, Pugliese A, Speranza F: **Role of nitric oxide in HIV-1 infection: friend or foe?** *Lancet Infect Dis*. 2002; **2**(5): 273–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
165. Lin GL, McGinley JP, Drysdale SB, *et al.*: **Epidemiology and Immune Pathogenesis of Viral Sepsis.** *Front Immunol*. 2018; **9**: 2147.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
166. Delaloye J, Calandra T: **Invasive candidiasis as a cause of sepsis in the critically ill patient.** *Virulence*. 2014; **5**(1): 161–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
167. Hübner MP, Layland LE, Hoerauf A: **Helminths and their implication in sepsis - a new branch of their immunomodulatory behaviour?** *Pathog Dis*. 2013; **69**(2): 127–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
168. López A, Lorente JA, Steingrub J, *et al.*: **Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock.** *Crit Care Med*. 2004; **32**(1): 21–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
169. Vincendeau P, Daulouède S, Veyret B, *et al.*: **Nitric oxide-mediated cytostatic activity on Trypanosoma brucei gambiense and Trypanosoma brucei brucei.** *Exp Parasitol*. 1992; **75**(3): 353–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
170. Sternberg J, Mabbott N, Sutherland I, *et al.*: **Inhibition of nitric oxide synthesis leads to reduced parasitemia in murine Trypanosoma brucei infection.** *Infect Immun*. 1994; **62**(5): 2135–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
171. Green SJ, Scheller LF, Marletta MA, *et al.*: **Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens.** *Immunol Lett*. 1994; **43**(1–2): 87–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
172. Naslund PK, Miller WC, Granger DL: **Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells.** *Infect Immun*. 1995; **63**(4): 1298–304.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
173. Chiwakata CB, Hemmer CJ, Dietrich M: **High levels of inducible nitric oxide synthase mRNA are associated with increased monocyte counts in blood and have a beneficial role in Plasmodium falciparum malaria.** *Infect Immun*. 2000; **68**(1): 394–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
174. Adajala AA, Watson M, Toner ES, *et al.*: **Characteristics of Microbes Most Likely to Cause Pandemics and Global Catastrophes.** *Curr Top Microbiol Immunol*. 2019; **424**: 1–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

175. Lorenz C, Azevedo TS, Chiaravallotti-Neto F: **COVID-19 and dengue fever: A dangerous combination for the health system in Brazil.** *Travel Med Infect Dis.* 2020; **35**: 101659.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
176. Haqqi A, Khurram M, Din MSU, *et al.*: **COVID-19 and Salmonella Typhi co-epidemics in Pakistan: A real problem.** *J Med Virol.* 2020.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
177. Haqqi A, Awan UA, Ali M, *et al.*: **COVID-19 and dengue virus coepidemics in Pakistan: A dangerous combination for an overburdened healthcare system.** *J Med Virol.* 2020.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
178. Wilson ME: **What goes on board aircraft? Passengers include Aedes, Anopheles, 2019-nCoV, dengue, Salmonella, Zika, et al.** *Travel Med Infect Dis.* 2020; **33**: 101572.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
179. Academy Medical Sciences: *Preparing for a challenging winter 2020/21.* London: Academy Medical Sciences; 2020.
180. Adalja A, Inglesby T: **Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool.** *Expert Rev Anti Infect Ther.* 2019; **17**(7): 467–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
181. Galloway JB, Norton S, Barker RD, *et al.*: **A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study.** *J Infect.* 2020.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
182. Horby P, Lim WS, Emberson JR, *et al.*: **Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.** *N Engl J Med.* 2020.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
183. The REMAP-CAP Investigators: **Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report.** *medRxiv.* 2021.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
184. Rahmani H, Davoudi-Monfared E, Nourian A, *et al.*: **Interferon β -1b in treatment of severe COVID-19: A randomized clinical trial.** *Int Immunopharmacol.* 2020; **88**: 106903.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
185. Mattner J, Schindler H, Diefenbach A, *et al.*: **Regulation of type 2 nitric oxide synthase by type 1 interferons in macrophages infected with Leishmania major.** *Eur J Immunol.* 2000; **30**(8): 2257–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
186. Utaisincharoen P, Anuntagool N, Limposuwan K, *et al.*: **Involvement of beta interferon in enhancing inducible nitric oxide synthase production and antimicrobial activity of Burkholderia pseudomallei-infected macrophages.** *Infect Immun.* 2003; **71**(6): 3053–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
187. Floyd CN, Shahed F, Ukah F, *et al.*: **Acute Blood Pressure-Lowering Effects of Nitrogen Dioxide Exposure From Domestic Gas Cooking Via Elevation of Plasma Nitrite Concentration in Healthy Individuals.** *Circ Res.* 2020; **127**(6): 847–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
188. Karupiah G, Xie QW, Buller RM, *et al.*: **Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase.** *Science.* 1993; **261**(5127): 1445–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
189. Mannick JB, Asano K, Izumi K, *et al.*: **Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation.** *Cell.* 1994; **79**(7): 1137–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
190. Croen KD: **Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication.** *J Clin Invest.* 1993; **91**(6): 2446–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
191. Harris N, Buller RM, Karupiah G: **Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication.** *J Virol.* 1995; **69**(2): 910–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
192. Mělková Z, Esteban M: **Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase.** *J Immunol. (Baltimore, Md. 1950).* 1995; **155**(12): 5711–8.
[PubMed Abstract](#)
193. Liu C, Wen L, Xiao Q, *et al.*: **Nitric oxide-generating compound GSNO suppresses porcine circovirus type 2 infection in vitro and in vivo.** *BMC Vet Res.* 2017; **13**(1): 59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
194. Wei ZY, Wang XB, Ning XD, *et al.*: **Nitric oxide inhibits the replication cycle of porcine parvovirus in vitro.** *Arch Virol.* 2009; **154**(6): 999–1003.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
195. Pertile TL, Karaca K, Sharma JM, *et al.*: **An antiviral effect of nitric oxide: inhibition of reovirus replication.** *Avian Dis.* 1996; **40**(2): 342–8.
[PubMed Abstract](#)
196. Zaragoza C, Ocampo CJ, Saura M, *et al.*: **Nitric oxide inhibition of coxsackievirus replication in vitro.** *J Clin Invest.* 1997; **100**(7): 1760–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
197. Takhampunya R, Padmanabhan R, Ubol S: **Antiviral action of nitric oxide on dengue virus type 2 replication.** *J Gen Virol.* 2006; **87**(Pt 10): 3003–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
198. Mannick JB, Stamler JS, Teng E, *et al.*: **Nitric oxide modulates HIV-1 replication.** *J Acquir Immune Defic Syndr.* 1999; **22**(1): 1–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
199. Lin YL, Huang YL, Ma SH, *et al.*: **Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication.** *J Virol.* 1997; **71**(7): 5227–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
200. Fata-Hartley CL, Palmenberg AC: **Dipyridamole reversibly inhibits mengovirus RNA replication.** *J Virol.* 2005; **79**(17): 11062–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
201. Tucker PC, Griffin DE, Choi S, *et al.*: **Inhibition of nitric oxide synthesis increases mortality in Sindbis virus encephalitis.** *J Virol.* 1996; **70**(6): 3972–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
202. Tonew E, Indulen MK, Dzeguze DR: **Antiviral action of dipyridamole and its derivatives against influenza virus A.** *Acta Virol.* 1982; **26**(3): 125–9.
[PubMed Abstract](#)
203. Rimmelzwaan GF, Baars MM, de Lijster P, *et al.*: **Inhibition of influenza virus replication by nitric oxide.** *J Virol.* 1999; **73**(10): 8880–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
204. Regev-Shoshani G, Vimalanathan S, McMullin B, *et al.*: **Gaseous nitric oxide reduces influenza infectivity in vitro.** *Nitric Oxide.* 2013; **31**: 48–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
205. Guidotti LG, McClary H, Loudis JM, *et al.*: **Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice.** *J Exp Med.* 2000; **191**(7): 1247–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
206. Klingström J, Åkerström S, Hardestam J, *et al.*: **Nitric oxide and peroxynitrite have different antiviral effects against hantavirus replication and free mature virions.** *Eur J Immunol.* 2006; **36**(10): 2649–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
207. Zheng S, De BP, Choudhary S, *et al.*: **Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis.** *Immunity.* 2003; **18**(5): 619–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
208. Ubol S, Hiriote W, Anuntagool N, *et al.*: **A radical form of nitric oxide suppresses RNA synthesis of rabies virus.** *Virus Res.* 2001; **81**(1–2): 125–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
209. Bi Z, Reiss CS: **Inhibition of vesicular stomatitis virus infection by nitric oxide.** *J Virol.* 1995; **69**(4): 2208–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
210. Akarid K, Sinet M, Desforges B, *et al.*: **Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo.** *J Virol.* 1995; **69**(11): 7001–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
211. McMullin BB, Chittock DR, Roscoe DL, *et al.*: **The antimicrobial effect of nitric oxide on the bacteria that cause nosocomial pneumonia in mechanically ventilated patients in the intensive care unit.** *Respir Care.* 2005; **50**(11): 1451–6.
[PubMed Abstract](#)
212. Jiang X, Leonard B, Benson R, *et al.*: **Macrophage control of Brucella abortus: role of reactive oxygen intermediates and nitric oxide.** *Cell Immunol.* 1993; **151**(2): 309–19.
[PubMed Abstract](#) | [Publisher Full Text](#)
213. Mayer J, Woods ML, Vavrin Z, *et al.*: **Gamma interferon-induced nitric oxide production reduces Chlamydia trachomatis infectivity in McCoy cells.** *Infect Immun.* 1993; **61**(2): 491–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
214. Park J, Rikihisa Y: **L-arginine-dependent killing of intracellular Ehrlichia risticii by macrophages treated with gamma interferon.** *Infect Immun.* 1992; **60**(9): 3504–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
215. Anthony LS, Morrissey PJ, Nano FE: **Growth inhibition of Francisella tularensis live vaccine strain by IFN-gamma-**

- activated macrophages is mediated by reactive nitrogen intermediates derived from L-arginine metabolism. *J Immunol.* (Baltimore, Md: 1950). 1992; **148**(6): 1829–34.
[PubMed Abstract](#)
216. Summersgill JT, Powell LA, Buster BL, *et al.*: Killing of *Legionella pneumophila* by nitric oxide in gamma-interferon-activated macrophages. *J Leukoc Biol.* 1992; **52**(6): 625–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 217. Feng HM, Walker DH: Interferon-gamma and tumor necrosis factor-alpha exert their antirickettsial effect via induction of synthesis of nitric oxide. *Am J Pathol.* 1993; **143**(4): 1016–23.
[PubMed Abstract](#) | [Free Full Text](#)
 218. de Giusti M, de Vito E: Inactivation of *Yersinia enterocolitica* by nitrite and nitrate in food. *Food Addit Contam.* 1992; **9**(5): 405–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 219. Morris SL, Hansen JN: Inhibition of *Bacillus cereus* spore outgrowth by covalent modification of a sulfhydryl group by nitrosothiol and iodoacetate. *J Bacteriol.* 1981; **148**(2): 465–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 220. Wakabayashi K, Nagai A, Sheikh AM, *et al.*: Transplantation of human mesenchymal stem cells promotes functional improvement and increased expression of neurotrophic factors in a rat focal cerebral ischemia model. *Journal of neuroscience research.* 2010; **88**(5): 1017–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
 221. Jones M, Ganopolsky JG, Labbé A, *et al.*: Novel nitric oxide producing probiotic wound healing patch: preparation and in vivo analysis in a New Zealand white rabbit model of ischaemic and infected wounds. *Int Wound J.* 2012; **9**(3): 330–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
 222. Denis M: Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent *Mycobacterium avium* and to kill avirulent *M. avium*: killing effector mechanism depends on the generation of reactive nitrogen intermediates. *J Leukoc Biol.* 1991; **49**(4): 380–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 223. Adams LB, Franzblau SG, Vavrin Z, *et al.*: L-arginine-dependent macrophage effector functions inhibit metabolic activity of *Mycobacterium leprae*. *J Immunol.* (Baltimore, Md: 1950) 1991; **147**(5): 1642–6.
[PubMed Abstract](#)
 224. Phillips R, Kuijper S, Benjamin N, *et al.*: In vitro killing of *Mycobacterium ulcerans* by acidified nitrite. *Antimicrob Agents Chemother.* 2004; **48**(8): 3130–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 225. Lin JY, Chadee K: Macrophage cytotoxicity against *Entamoeba histolytica* trophozoites is mediated by nitric oxide from L-arginine. *J Immunol.* (Baltimore, Md: 1950). 1992; **148**(12): 3999–4005.
[PubMed Abstract](#)
 226. Fischer-Stenger K, Marciano-Cabral F: The arginine-dependent cytolytic mechanism plays a role in destruction of *Naegleria fowleri* amoebae by activated macrophages. *Infect Immun.* 1992; **60**(12): 5126–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 227. Haswell-Elkins MR, Satarug S, Tsuda M, *et al.*: Liver fluke infection and cholangiocarcinoma: model of endogenous nitric oxide and extragastric nitrosation in human carcinogenesis. *Mutat Res.* 1994; **305**(2): 241–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
 228. Orjuela-Sánchez P, Ong PK, Zanini GM, *et al.*: Transdermal glyceryl trinitrate as an effective adjunctive treatment with artemether for late-stage experimental cerebral malaria. *Antimicrob Agents Chemother.* 2013; **57**(11): 5462–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 229. James SL, Glaven J: Macrophage cytotoxicity against schistosomula of *Schistosoma mansoni* involves arginine-dependent production of reactive nitrogen intermediates. *J Immunol.* (Baltimore, Md: 1950). 1989; **143**(12): 4208–12.
[PubMed Abstract](#)
 230. Shen J, Lai DH, Wilson RA, *et al.*: Nitric oxide blocks the development of the human parasite. *Proc Natl Acad Sci U S A.* 2017; **114**(38): 10214–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 231. Kawakami NY, Tomiotto-Pellissier F, Cataneo AH, *et al.*: Sodium nitroprusside has leishmanicidal activity independent of iNOS. *Rev Soc Bras Med Trop.* 2016; **49**(1): 68–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 232. Adams LB, Hibbs JB, Taintor RR, *et al.*: Microbiostatic effect of murine-activated macrophages for *Toxoplasma gondii*. Role for synthesis of inorganic nitrogen oxides from L-arginine. *J Immunol.* (Baltimore, Md: 1950) 1990; **144**(7): 2725–9.
[PubMed Abstract](#)
 233. Hayashi S, Chan CC, Gazzinelli RT, *et al.*: Protective role of nitric oxide in ocular toxoplasmosis. *Br J Ophthalmol.* 1996; **80**(7): 644–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 234. Gross NT, Nessa K, Camner P, *et al.*: Production of nitric oxide by rat alveolar macrophages stimulated by *Cryptococcus neoformans* or *Aspergillus fumigatus*. *Med Mycol.* 1999; **37**(3): 151–7.
[PubMed Abstract](#)
 235. Lane TE, Wu-Hsieh BA, Howard DH: Antihistoplasma effect of activated mouse splenic macrophages involves production of reactive nitrogen intermediates. *Infect Immun.* 1994; **62**(5): 1940–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 236. Downing JF, Kachel DL, Pasula R, *et al.*: Gamma interferon stimulates rat alveolar macrophages to kill *Pneumocystis carinii* by L-arginine- and tumor necrosis factor-dependent mechanisms. *Infect Immun.* 1999; **67**(3): 1347–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 237. Cenci E, Romani L, Mencacci A, *et al.*: Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of *Candida albicans*. *Eur J Immunol.* 1993; **23**(5): 1034–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 238. Alspaugh JA, Granger DL: Inhibition of *Cryptococcus neoformans* replication by nitrogen oxides supports the role of these molecules as effectors of macrophage-mediated cytostasis. *Infect Immun.* 1991; **59**(7): 2291–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 239. Stasko N, McHale K, Hollenbach SJ, *et al.*: Nitric Oxide-Releasing Macromolecule Exhibits Broad-Spectrum Antifungal Activity and Utility as a Topical Treatment for Superficial Fungal Infections. *Antimicrob Agents Chemother* 2018; **62**(7).
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 240. Hall CN, Garthwaite J: What is the real physiological NO concentration in vivo? *Nitric Oxide.* 2009; **21**(2): 92–103.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 241. Ohta K, Rosner G, Graf R: Nitric oxide generation from sodium nitroprusside and hydroxylamine in brain. *Neuroreport.* 1997; **8**(9-10): 2229–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
 242. Bátai I, Kerényi M, Tekeres M: The growth of bacteria in intravenous glyceryl trinitrate and in sodium nitroprusside. *Anesth Analg.* 1999; **89**(6): 1570–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
 243. Barraud N, Storey MV, Moore ZP, *et al.*: Nitric oxide-mediated dispersal in single- and multi-species biofilms of clinically and industrially relevant microorganisms. *Microb Biotechnol.* 2009; **2**(3): 370–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 244. Miller C, McMullin B, Ghaffari A, *et al.*: Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. *Nitric Oxide.* 2009; **20**(1): 16–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
 245. Jones ML, Ganopolsky JG, Labbé A, *et al.*: A novel nitric oxide producing probiotic patch and its antimicrobial efficacy: preparation and in vitro analysis. *Appl Microbiol Biotechnol.* 2010; **87**(2): 509–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
 246. Tonew M, Tonew E, Mentel R: The antiviral activity of dipyridamole. *Acta Virol.* 1977; **21**(2): 146–50.
[PubMed Abstract](#)
 247. Booth L, Roberts JL, Cash DR, *et al.*: GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease. *J Cell Physiol.* 2015; **230**(7): 1661–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 248. Roberts JL, Tavallai M, Nourbakhsh A, *et al.*: GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases. *J Cell Physiol.* 2015; **230**(10): 2552–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 249. Hardwick JB, Tucker AT, Wilks M, *et al.*: A novel method for the delivery of nitric oxide therapy to the skin of human subjects using a semi-permeable membrane. *Clin Sci (Lond).* 2001; **100**(4): 395–400.
[PubMed Abstract](#)
 250. Riccio DA, Schoenfish MH: Nitric oxide release: part I. Macromolecular scaffolds. *Chem Soc Rev.* 2012; **41**(10): 3731–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

251. Jin H, Yang L, Ahonen MJR, *et al.*: **Nitric Oxide-Releasing Cyclodextrins**. *J Am Chem Soc.* 2018; **140**(43): 14178–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
252. Sadrearhami Z, Nguyen TK, Namivandi-Zangeneh R, *et al.*: **Recent advances in nitric oxide delivery for antimicrobial applications using polymer-based systems**. *J Mater Chem B.* 2018; **6**(19): 2945–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
253. Sharma K, Sengupta K, Chakrapani H: **Nitroreductase-activated nitric oxide (NO) prodrugs**. *Bioorg Med Chem Lett.* 2013; **23**(21): 5964–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
254. Hibbard HAJ, Reynolds MM: **Synthesis of novel nitroreductase enzyme-activated nitric oxide prodrugs to site-specifically kill bacteria**. *Bioorg Chem.* 2019; **93**: 103318.
[PubMed Abstract](#) | [Publisher Full Text](#)
255. Alvarez RA, Berra L, Gladwin MT: **Home Nitric Oxide Therapy for COVID-19**. *Am J Respir Crit Care Med.* 2020; **202**(1): 16–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status: ?

Version 1

Reviewer Report 27 September 2021

<https://doi.org/10.5256/f1000research.54420.r93464>

© 2021 Kashfi K. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Khosrow Kashfi

Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY, 10031, USA

Nitric oxide (NO) is one of the ten smallest molecules found in nature. It is released intracellularly when L-arginine is oxidized by the enzyme nitric oxide synthase (NOS), of which there are three isoforms. Neuronal (nNOS, NOS1) and endothelial (eNOS, NOS3) are constitutive calcium-dependent forms of the enzyme regulated by negative feedback and release low fluxes of NO over a short period regulating neural and vascular function, respectively. The third isoform (iNOS, NOS2) is calcium-independent, inducible, produces supra-physiological concentrations of NO, and is involved in immune surveillance. NO can also be produced through the reduction of nitrite/nitrate under low oxygen conditions.

NO has important roles in normal physiology, exemplified by regulation of vascular relaxation, control of inflammation by inhibiting NF- κ B activation, and suppression of pro-inflammatory mediators in mast cells, macrophages, and vascular smooth muscles. In addition, NO regulates blood flow, modulates platelet and leukocyte activation, adhesion, and aggregation.

In this review, the authors have focused on NO's role in defense against multiple microbial pathogens [including viruses, bacteria, SARS-CoV (COVID-19), protozoa, and fungi/yeast]. In addition, they have highlighted the possibility that exogenous NO might have therapeutic potential as a broad-spectrum antimicrobial. Finally, they have also summarized various NO donating/releasing platforms.

In general, I do not think that there is a "right" or "wrong" way of presenting a review, as long as it is accurate, balanced, and gives adequate historical background. I found this review to be quite compelling and of interest to those starting in this field and an update for the seasoned investigators. In short, it is an authoritative review. For the novice, the review gives the directions for further in-depth reading. Finally, I would like to make some suggestions to the text for the authors to consider as I believe it would add to the overall body of this work.

- Throughout the text, when you talk about "NO may be taken as dietary substrate (inorganic

nitrate, L-arginine)...", please also discuss L-citrulline as a source of NO. We recently reviewed this topic and you may want to use this review as a source to expand on this¹.

- In Table 1, please add L-citrulline as a substrate and give the appropriate biochemical equation.
- Under Therapeutic inorganic nitrite and nitrate, please consider adding the use of nitrite/nitrate in animal models of wound healing. Refer to Afzali *et al.* 2020² for an introduction to this.
- Under novel nitric oxide agents, please add RRx-001, which is a novel NO modulator³.
- As summarized in the review, dietary intake of foods such as beetroot that are rich as a source of nitrate have many health benefits. And as mentioned, "Dietary nitrate has profound metabolic effects and appears to have the potential for reversing the metabolic syndrome and have anti-diabetic effects.". However, although the beneficial metabolic effects of inorganic nitrate and nitrite in type 2 diabetes mellitus have been documented in animal experiments, this is not the case for humans. Perhaps this should be mentioned on page 18 of the review⁴.

References

1. Bahadoran Z, Mirmiran P, Kashfi K, Ghasemi A: Endogenous flux of nitric oxide: Citrulline is preferred to Arginine. *Acta Physiol (Oxf)*. **231** (3): e13572 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Afzali H, Khaksari M, Norouzirad R, Jeddi S, et al.: Acidified nitrite improves wound healing in type 2 diabetic rats: Role of oxidative stress and inflammation. *Nitric Oxide*. 2020; **103**: 20-28 [PubMed Abstract](#) | [Publisher Full Text](#)
3. Yalcin O, Oronsky B, Carvalho LJ, Kuypers FA, et al.: From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. *Malar J*. 2015; **14**: 218 [PubMed Abstract](#) | [Publisher Full Text](#)
4. Bahadoran Z, Mirmiran P, Kashfi K, Ghasemi A: Lost-in-Translation of Metabolic Effects of Inorganic Nitrate in Type 2 Diabetes: Is Ascorbic Acid the Answer?. *Int J Mol Sci*. 2021; **22** (9). [PubMed Abstract](#) | [Publisher Full Text](#)

Is the topic of the review discussed comprehensively in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Is the review written in accessible language?

Yes

Are the conclusions drawn appropriate in the context of the current research literature?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pharmacologist with a strong background in biochemistry and intermediary metabolism.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 14 Oct 2021

Philip Bath, University of Nottingham, Nottingham, UK

Reviewer 1 responses

We thank Dr. Kashfi for his most helpful and considered comments and respond to each as below.

In this review, the authors have focused on NO's role in defense against multiple microbial pathogens [including viruses, bacteria, SARS-CoV (COVID-19), protozoa, and fungi/yeast]. In addition, they have highlighted the possibility that exogenous NO might have therapeutic potential as a broad-spectrum antimicrobial. Finally, they have also summarized various NO donating/releasing platforms.

In general, I do not think that there is a "right" or "wrong" way of presenting a review, as long as it is accurate, balanced, and gives adequate historical background. I found this review to be quite compelling and of interest to those starting in this field and an update for the seasoned investigators. In short, it is an authoritative review. For the novice, the review gives the directions for further in-depth reading. Finally, I would like to make some suggestions to the text for the authors to consider as I believe it would add to the overall body of this work.

- Throughout the text, when you talk about "NO may be taken as dietary substrate (inorganic nitrate, L-arginine)....", please also discuss L-citrulline as a source of NO. We recently reviewed this topic, and you may want to use this review as a source to expand on this¹.

We have added L-citrulline wherever dietary L-arginine is mentioned (abstract, text and tables), and added two references: Flam *et al.* 2007, Bahadoran *et al.* 2021.

- In Table 1, please add L-citrulline as a substrate and give the appropriate biochemical equation.

We have added L-citrulline as a substrate and the relevant equations.

- Under Therapeutic inorganic nitrite and nitrate, please consider adding the use of nitrite/nitrate in animal models of wound healing. Refer to Afzali *et al.* 2020² for an introduction to this.

We have added a comment relating to the reference of Afzali *et al.* 2020, and the reference itself.

- Under novel nitric oxide agents, please add RRx-001, which is a novel NO modulator³.

We have added a comment relating to RRx-001 using a reference from Oronsky *et al.*

2020, and the reference itself.

- As summarized in the review, dietary intake of foods such as beetroot that are rich as a source of nitrate have many health benefits. And as mentioned, "Dietary nitrate has profound metabolic effects and appears to have the potential for reversing the metabolic syndrome and have anti-diabetic effects.". However, although the beneficial metabolic effects of inorganic nitrate and nitrite in type 2 diabetes mellitus have been documented in animal experiments, this is not the case for humans. Perhaps this should be mentioned on page 18 of the review⁴.

We have added two references relating to beetroot juice improving insulin sensitivity and reducing blood glucose (Wootton *et al.* 2014, Beals *et al.* 2017).

Competing Interests: No competing interests were disclosed.

Comments on this article

Version 1

Author Response 19 Oct 2021

Philip Bath, University of Nottingham, Nottingham, UK

We thank Dr Taylor-Robinson for his comment reminding us of the importance of malaria and long history of research into the importance of nitric oxide with it having both protective and anti-immunological effects; we have added two references for this (Taylor-Robinson & Smith 1999, Shikani *et al.* 2012).

Competing Interests: Response from Philip Bath, lead/coordinating author.

Reader Comment 12 Jul 2021

Andrew Taylor-Robinson, Central Queensland University, Brisbane, Australia

While this is an otherwise authoritative review, an important oversight is the only one brief mention afforded to the role of nitric oxide (NO) and its various derivatives in host immunity to the malaria parasite, *Plasmodium*, a citation from as recent as 2013 (ref. 228).

Much is known of the protective - and pathological - effects triggered by NO metabolites in the mammalian immune response to asexual plasmodia, both during uncomplicated infection of the peripheral blood (PB) and cerebral malaria (CM) sequelae of parasitised erythrocyte sequestration.

Investigation of NO during malaria infection extends back to the late 1980s and throughout the 1990s, principally in murine models including *P. berghei* (mostly for CM) and *P. chabaudi* (mostly for PB). In many aspects, the pioneering research of the groups of Langhorne, Phillips, Stephenson,

Clark and Hunt, among others, led the field for what was then known about the role of NO in immunity to protozoan infection, as well as more broadly.

The implications of this collective body of work have been extrapolated extensively to other intracellular pathogens as they were reached by exploiting a tractable system for dissecting the evidently subtle balance between immune protection and immunopathology. The main findings remain very relevant to a contemporary consideration of the part played by NO in prevention and treatment of infectious diseases.

Competing Interests: I declare no competing interests.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research